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ABSTRACT
Antibiotics are compounds that kill or slow the growth of bacteria to treat
numerous bacterial infections. No new class of antibiotic has been identified in the
past thirty years despite the increased use of current antibiotics around the world.
The increased use of current antibiotics has contributed to bacterial species
becoming resistant to multiple antibiotics. Bacteria possess multiple resistance
mechanisms such as inactivating enzymes, mutation of the antibiotic’s target, the
permeability of the outer membrane, and the overexpression of efflux pumps.
Efflux pumps bind antibiotics and eject them from the bacteria. In
Escherichia coli (E. coli), the most studied efflux pump is referred to as AcrABTolC. Antibiotics bind AcrB triggering a series of conformational changes that expel
the drug from the cell. AcrAB-TolC is a tripartite machinery that spans the inner
and outer membrane of E. coli. AcrA is a periplasmic adaptor that links together
AcrB in the inner membrane with TolC in the outer membrane. Efflux pump
inhibitors (EPIs) have been developed that interact with AcrB and thus potentiate
the activity of specific antibiotics. The inhibitors act by competitive inhibition. Other
mechanisms of inhibition such as blocking drug export through TolC have not been
found to function in vivo.
In this work, we have identified new inhibitors that bind AcrA, inhibit efflux,
and potentiate specific antibiotics. We have identified the inhibitors using multiple
homology models of AcrA. For each homology model, we ran molecular dynamics
(MD) simulations and extracted conformations using RMSD clustering. Ligands
v

were predicted to bind by using the extracted conformations from each homology
model with the program AutoDock VinaMPI. For two of the inhibitors, referred to
as NSC60339 (SLU-258) and clorobiocin, we used AutoDock VinaMPI and a
binding site identification program called FTMap to identify and subsequently
validate possible binding sites on AcrA using tryptophan fluorescence
spectroscopy. Finally, we used the identified binding sites in conjunction with
physico-chemical descriptors to further identify new efflux pump inhibitors that
potentiate novobiocin, erythromycin, and bind AcrA with a new chemical scaffold
for efflux pump inhibitors.
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PREFACE
Bottom up thinkers try to start from experience and move from experience to
understanding. They don't start with certain general principles they think
beforehand are likely to be true; they just hope to find out what reality is like.
-

John Polkinghorne
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INTRODUCTION
Antibiotic resistance and the discovery void
Antibiotic resistance is a global public health concern that can impact every
person on the planet.1 Antibiotics are drugs, typically small organic molecules, that
kill or slow down the growth of bacteria during an infection.2 Antibiotics are grouped
into different classes depending on their intended target and mechanism of action.3
For example, b-lactams such as penicillin inhibit the synthesis of the bacterial cell
wall while aminoglycosides inhibit protein synthesis by interacting with the bacterial
ribosome.3 Ever since the first antibiotic, penicillin, was discovered by Alexander
Fleming in 1928,4 medical professionals have been prescribing antibiotics for the
prevention and treatment of bacterial infections.3 In addition, we have also applied
the use of antibiotics in agriculture.5 The cumulative result of different antibiotics
use has provoked a multipronged response from bacteria referred to as resistance.
In 1859, Charles Darwin published his book entitled On the Origin of
Species.6 In this book, Darwin laid out his theory of natural selection.6 Natural
selection in the context of antibiotic resistance states that when individual bacteria
are exposed to certain environmental conditions that threaten their survival (such
as the use of antibiotics), certain individuals in the species will adapt to resist these
conditions.7 The individuals that adapt are then selectively favored to pass on their
genes to the next generation.
The mechanism(s) of resistance obtained by the selectively favored
bacteria are wide and diverse. Bacteria can develop mutations in DNA gyrase, a
1

key enzyme responsible for DNA replication, which prevent antibiotics in the
quinolone class from inhibiting the enzyme.8 Bacteria can express b-lactamase
enzymes that bind and inactivate b-lactam antibiotics preventing them from
performing their mechanism of action.9 Resistant bacteria can also modulate the
influx and efflux of multiple classes of antibiotics.10, 11 In a sub-category of bacteria
referred to as Gram-negative, bacteria contain two membrane bilayers separated
by a space called the periplasm.12 The two membranes are referred to as the outer
and inner membrane (Figure 1). Antibiotics that enter the Gram-negative bacterial
cell can pass through a hydrophobic bilayer or through proteins called porins
embedded in the bilayer that contain a hydrophilic channel enabling antibiotic
passage.13 Bacteria can reduce the influx of antibiotics by decreasing the

Outer
Membrane

Cell Wall

Periplasm

Inner
Membrane

Figure 1. Depiction of the AcrAB-TolC efflux pump in its native environment with
the outer membrane, cell wall, periplasm, and inner membrane labeled. The
periplasm is the space between the outer and inner membrane.
2

expression of porins in the outer membrane.13 Bacteria can also transport
molecules known as lipopolysaccharides from the inner membrane to the outer
membrane.14 The lipopolysaccharides contain negatively charged sugar groups
that are then cross-linked by divalent cations to produce a highly charged polar
environment and provide a permeability barrier to antibiotics (Figure 2).15-17
Antibiotics that can bypass the outer membrane are confronted by a tripartite
molecular machine in the periplasm known as an efflux pump which ejects the
antibiotic from the bacterial cell (Figure 1).18
The combination of mutation of the intended drug target8, inactivating
enzymes, permeability barrier,10 and efflux are the bacterial responses to the
selective pressure induced by bacteria.12 These resistance mechanisms reduce
the efficacy of currently available antibiotics. Moreover, we are living in a discovery
void where a novel class of antibiotics has not been identified since the 1980s
(Figure 3).19

Figure 2. Molecular picture of the K-12 Gram-negative outer membrane. POPE
(orange) and POPG (green) is in the inner leaflet. Lipid A (grey) is in the outer
leaflet attached to the inner core polysaccharides (blue and red). Divalent cations,
magnesium (green) and calcium (pink), interact with the inner core
polysaccharides. The outer core polysaccharides are shown in magenta and black.
3

Figure 3. Discovery void of new classes of antibiotics. Figure was modified from
Public Health England.
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Structure and function of multidrug efflux pumps in Escherichia
coli
About 80% of bacterial infections diagnosed in a hospital setting have been
attributed to a multidrug Gram-negative species such as Escherichia coli (E.
coli).20-22 E. coli infections are the leading cause of urinary tract infections (UTIs)
and are often related to food-born infections such as in beef and romaine lettuce.2325

During growth, E. coli produce metabolites that are toxic to the cell and need to

be removed for proper cell development.26 E. coli utilize efflux pumps such as
AcrAB-TolC that span both membranes and the entire periplasm to extrude these
metabolites (Figure 1). In the case of a food-born infection from undercooked beef
or romaine lettuce, E. coli travels through the small intestine where bile acids are
released and negatively harm the DNA of E. coli.27 The presence of bile acids
induces the expression of AcrAB-TolC which expel the bile from the periplasm and
prevent it from reaching the DNA in the bacterial cell.28 AcrAB-TolC is a complex
machinery composed of three proteins from different families: ResistanceNodulation-Division (RND), Membrane fusion proteins (MFP), and outer
membrane factors (OMF).26, 29
AcrB is a homotrimer of the RND family composed of 1049 amino acids with
a transmembrane, periplasmic (porter), and funnel domain.30 AcrB is expressed
as a functional unit with AcrA. AcrB can bind and extrude a range of compounds
from bile acids, dyes (acraflavine), detergents (sodium dodecyl sulfate (SDS),
solvents, and antibiotics.18,

26, 31

Antibiotics include novobiocin, erythromycin,

penicillin, and levofloxacin.31 These antibiotics are from four different classes of
5

antibiotics

such

as

aminocoumarin32,

macrolide33,

b-lactam4,

34

,

and

fluoroquinolones35; thus, AcrB exhibits a polyspecific character that contributes to
multidrug resistance.
AcrB as a trimer can exist in three different conformational states referred
to as loose (L), tight (T), and open (O).30, 36 A molecule, substrate, enters AcrB in
the L state through 3 possible open channels: a lower periplasmic cleft, a cleft on
the surface of the inner membrane, or through a central cavity in the
transmembrane domain (Figure 4).37 Transport through the central cavity is
involved in transport of substrates directly from the interior of the cell.37 When a
substrate enters one of the three channels in the L state, the distal pocket expands
to facilitate binding in the T state after binding or bypassing another pocket referred
to as the access pocket.38, 39 The two pockets are separated a by loop referred to
as a switch-loop or G-loop.40 Substrates with a high molecular weight such as
erythromycin bind at the access pocket while lighter substrates bypass the switchloop and bind the distal pocket.38 Substrates that enter through the central cavity
can bypass the access pocket and directly bind the distal pocket.37 A proton
gradient between aspartic acid residues in the transmembrane domain triggers
conformational changes that closes the open channels, shrinks the distal binding
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Figure 4. Structure and substrate transport pathways of AcrB. (A) AcrB in three
conformational states with transmembrane, porter, and funnel domains highlighted
(PDB 4DX5). The L state is in yellow, T state in red, and O state in green. (B) The
substrate can enter from a cleft in the periplasm (brown sphere; R307), traverse
through the access binding pocket (yellow spheres), the G-loop (magenta ribbon),
and distal binding pocket (blue sphere) to the exit gate (cyan spheres; Y758, K770)
which passes the substrate into the funnel domain and towards TolC. (C)
Alternatively, substrate can center from the surface of the inner membrane (black
spheres; D566, T678). (D) Substrate can enter from the central cavity (orange
spheres; T37, A100) and traverse directly to the distal binding pocket and then
onwards to the exit gate and out of the cell.
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pocket, and opens a gate into the central funnel towards TolC.39, 41 The substrate
is pushed out of the cell by a peristaltic motion resulting in a functional rotation
mechanism (Figure 5).36
AcrB assembles with two other proteins, AcrA and TolC, to expel substrates
from the cell.42 AcrA is a periplasmic adaptor from the MFP family.43 It consists of
four domains referred to as the a-hairpin, lipoyl, b-barrel, and membrane-proximal
(MP).44 The lipoyl, b-barrel, and MP domain interact with AcrB while the a-hairpin
interacts with TolC.44, 45 TolC is a trimer from the OMF family and consists of a 12
stranded b-barrel protein embedded in the outer membrane that is constitutively
open to the environment.26, 39, 46 In addition, TolC consists of 12 a-helices that
extend into the periplasm (Figure 6).46 The periplasmic tip contains a ring of
aspartate residues that keep the pore in a closed state preventing substrate access
(Figure 6). 39
Until the determination of near-atomic resolution cryo-EM structures, the
oligomeric state of AcrA and the structure of the assembled complex remained
unclear.29, 44, 47 The first model of the assembled complex used in vivo crosslinking
with protein-protein docking to build a model with 3:3:3 stoichiometry.44 AcrB, AcrA,
and TolC assemble as trimers.30, 46, 47 The model asserted that AcrA binds AcrB
as a monomer, but gel filtration chromatography combined with surface plasmon
resonance (SPR) concluded that the binding affinity of AcrA to AcrB is an order of
magnitude higher when the N-terminus of AcrA is lipid-modified and acts as a
dimer.42, 44 In vivo, AcrA is known to be anchored to the inner membrane by a
8
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Figure 5. Drug transport mechanism of AcrB. (A) Functional rotation mechanism
of AcrB. An efflux pump substrate such as acridine (shown) enters AcrB in the L
state triggering conformational changes that expand the distal binding pocket in
the T state. A proton relay mechanism triggers a subsequent conformational
change that collapses the distal pocket and expels the substrate towards TolC for
efflux in the O state. (B) In the absence of substrate, gaps exist between AcrA
dimers in the hexameric funnel. (C) The gaps are sealed upon substrate binding
and functional rotation in AcrB to propagate efflux out of the cell. The sealing of
the gaps in AcrA switches TolC into an open state.
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Figure 6. (A) The atomic structure of TolC (PDB ITQQ). The closed (B) and open
states (C) of TolC from the apo (closed) and inhibitor-bound (open) cryo-EM
structures (PDB 5V5S and 5NG5). Each state is differentiated by two aspartic acid
residues, Asp371 and Asp374, in each monomer of TolC.

lipid.48 The binding of an AcrA dimer to a trimeric AcrB results in AcrA assembling
as a hexmeric funnel around AcrB (Figure 1).49 The hexameric structure of AcrA
has also been confirmed in the cellular environment in situ using cryo-EM
imaging.50 The question though of how AcrA connects AcrB and TolC was still in
question.
Two models were proposed for how AcrA functions as an adaptor between
AcrB and TolC. The first is referred to as the adaptor wrapping model.26 In this
model, AcrB and TolC directly interact and hexameric AcrA interacts with TolC and
AcrB to wrap around the two proteins. AcrB was found to directly interact with TolC
by disulfide crosslinking and bind with nanomolar affinity using SPR.42,

51

The

binding affinity between AcrB and TolC was comparable to AcrA and AcrB.42 In
contrast, cryo-electron microscopy (EM) found that AcrA functions as a trimer of
dimers to form a hexameric funnel that bridges AcrB and TolC.29, 39, 45, 49 There is
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no direct interaction between AcrB and TolC. This is called the adaptor bridging
model26 and cryo-EM has found that the model agrees with structures from other
efflux transporters such as MexAB-OprM in Pseudomonas aeruginosa, CusABC,
and MacAB-TolC in Escherichia coli.52-54
In cryo-EM structures of AcrAB-TolC with and without a ligand bound, the
complete mechanism of substrate transport from AcrB to TolC was elucidated.
AcrAB-TolC

transports

substrates

by

a

long-range

allosteric

transport

mechanism.39 In the absence of substrate, the periplasmic tip of TolC is constricted
resulting in a closed state (Figure 6). AcrA acts a trimer of dimers to bridge AcrB
with TolC and contains small gaps in between each dimer (Figure 5B). Upon
substrate binding AcrB in the L state, the gaps in AcrA are sealed to prevent
substrate leakage (Figure 5C) and TolC transitions to an open state to allow
substrate passage (Figure 6).39 Forced partial opening of TolC by mutants at the
periplasmic tip lead to a decrease in TolC’s affinity for AcrA.42, 55 This indicates that
the open state of TolC is less stable, which could lead to disassembly upon
substrate transport.55 TolC is an outer membrane protein that is involved in other
transporters in E. coli such as AcrDA-TolC, AcrEF-TolC, and MacAB-TolC.26 This
disassembly of AcrAB-TolC is necessary for TolC to interact with other
transporters.

Efflux pump inhibition
To overcome resistance, the long-range allosteric mechanism by which
multidrug efflux pumps function must be inhibited.56,

57

A plausible solution is
11

combination therapy.58,

59

Combination therapy is interim until a new class of

antibiotics can be discovered for treatment of bacterial infections, but could also
be used to restore the activity of existing antibiotics from resistance.57 The coadministration of an antibiotic with an efflux pump inhibitor (EPI) prevents the
emergence of new mutant strains reducing the frequency of resistance to a specific
target.56 Overexpression of AcrAB-TolC is correlated with a reduction of DNA
mismatch repair proteins resulting in a higher frequency of spontaneous mutation;
thus, inhibition of efflux with EPIs helps to prevent the early stages of antibiotic
resistance by hindering the ability of the bacteria to mutate the intended target of
the antibiotic.60, 61
An EPI that targets multidrug efflux pumps such as AcrAB-TolC in Gramnegative bacteria should ideally have seven qualities. An EPI for a specific efflux
pump such as AcrAB-TolC should be able to bypass the permeability barrier of the
OM (i), potentiate the activity of antibiotics that are efflux pump substrates (ii), don’t
potentiate antibiotics in efflux-deficient cells (iii), increase the accumulation of
substrates inside the cell (iv), not affect the proton relay across the inner
membrane (v), have no antibacterial activity (vi), and not potentiate antibiotics that
are non-substrates (vii). 35, 61, 62 An EPI that possesses these qualities would likely
have a mechanism of action for AcrAB-TolC.
The first discovered EPI was PAbN (MC-207,110) (Figure 7A).35 MC207,110 was discovered through a high-throughput experimental screen of
200,000 compounds that potentiated the antibiotic levofloxacin, a fluoroquinolone
12
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Figure 7. Chemical structure of current efflux pump inhibitors MC-207,110 (A) and
MBX2319 (B).
and efflux pump substrate, in Pseudomonas aeruginosa (P. aeruginosa) and E.
coli.35,

62

The compound also inhibited AcrAB-TolC in E. coli, but with less

potentiation of levofloxacin than P. aeruginosa.62 Inhibition of efflux by MC-207,110
in E. coli was observed by the increased fluorescence and accumulation of a
fluorescent dye referred to as Hoechst H33342.62 Hoechst H33342 is a known
efflux pump substrate that intercalates with DNA inside the cell.62, 63 When an efflux
pump such as AcrAB-TolC is functional, Hoechst H33342 is ejected resulting in
lower fluorescence compared to efflux-deficient cells.63 The co-administration of
an EPI such as MC-207,110 increases the fluorescence of the dye compared to
wild-type cells.62 Additionally, MC-207,110 exhibited two more the qualities of an
EPI by having no intrinsic antibacterial activity and not disturbing the proton
gradient across the inner membrane.35, 57
Although, MC-207,110 is no longer in drug development because it lacks
two of the qualities for an EPI: it potentiates antibiotics that are non-substrates,
13

specifically gentamicin, in WT and efflux-deficient cells.62 Efflux-deficient cells are
mutants where either the TolC or AcrB genes have been deleted by site-directed
mutagenesis.62 In efflux-deficient cells, MC-207,110 was found to possess an
additional mode of action.62 MC-207,110 disrupted the integrity of the outer
membrane and thus increased the influx and susceptibility of antibiotics.57 The
additional mode of action indicates that MC-207,110 can bypass the outer
membrane permeability barrier of Gram-negative bacteria typical of an EPI, but the
ability to do so in efflux-deficient cells indicates that the compound contains toxicity
issues limiting development.64 Toxicity can be defined as eliciting a drug response
from an unintended target. MC-207,110 can potentiate a non-substrate of AcrABTolC; therefore, it is exerting unintended responses. Responses that are beyond
the inhibition of AcrAB-TolC. Further development of analogs using the MC207,110 scaffold were ended because of toxicity.62
A separate independent whole cell high-throughput screen of 183,400
compounds identified a compound referred to as MBX2319 that contains a
pyranopyridine scaffold that has become the basis for one of the most potent types
of EPIs to date (Figure 7B).61, 65 MBX2319 potentiates fluoroquinolone and blactam antibiotics that are efflux pump substrates, doesn’t potentiate nonsubstrates, doesn’t potentiate substrates in efflux-deficient cells, contains no
intrinsic antibacterial activity, increases the accumulation of Hoechst H33342, and
doesn’t perturb the proton gradient across the inner membrane or disrupt influx
across the outer membrane like MC-207,110.62 The permeability of MBX2319 is
14

unknown, but the ability to potentiate antibiotics in WT cells suggests that
permeability is not an issue.
X-ray crystal structures have been determined for MBX2319 and three
analogs derived from the same scaffold.66 The structures found that all the
compounds bind the hydrophobic trap of the distal binding pocket of AcrB.66, 67 The
hydrophobic trap is characterized by six phenylalanine residues; thus, the
compounds interact with AcrB through van der waals and p-p stacking interactions
(Figure 8).66, 67 The crystallographic poses for the compounds overlap with the
crystallographic pose of minocycline to AcrB, a tetracycline antibiotic and AcrB
substrate.66, 68 Kinetic assays confirmed that MBX2319 and the three analogs act
as competitive inhibitors of AcrB.62, 65 The binding of the inhibitors outcompetes
the binding of the antibiotics to the pump; thus, a greater concentration of antibiotic
remains inside the cell. A complete structure-activity relationship (SAR) has been
devised and identified the sections of the pyranopyridine scaffold that most
contribute to potency. Sixty analogs were developed for this SAR, but none of the
compounds have reached clinical development.

65, 69

While both MC-207,110 and MBX2319 have been potential lead
compounds for clinical use, none of their analogs have made It into the Food and
Drug Administration (FDA) clinical phase development.61 Both MC-207,110 and
MBX2319 have different proposed mechanisms of action on AcrB. MC-207,110
was proposed by computational methods to bind at the G-loop and allosterically
prevent substrate access as means of inhibiting efflux while MBX2319 inhibits
15

Figure 8. MBX2319 (cyan) is surrounded by six phenylalanine residues (purple) in
the hydrophobic trap of the distal binding pocket of AcrB. The six phenylalanine
residues are F136, F178, F610, F615, F617, and F628.
competively.40, 62 Perhaps some new mechanisms of action are needed to discover
a lead with clinical applications.

TolC as a poor drug target
To inhibit the AcrAB-TolC efflux pump through mechanisms other than
AcrB, one of the possible targets is TolC. TolC is the outer membrane channel for
efflux pumps in E. coli to expel antibiotics and other substrates from the cell.26 If a
molecule could be discovered that blocks the TolC channel, efflux should be
inhibited. A molecule referred to as hexamminecobalt was co-crystallized with TolC
and found to interact with the aspartate ring.70 The aspartate ring expands and
constricts to create the open and closed states of TolC (Figure 9).39, 46 The binding
of hexamminecobalt conceivably keeps TolC in a closed state blocking efflux of
antibiotics from AcrB. Hexamminecobalt binds TolC in the sub-micromolar range,
16
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Figure 9. Hexamminecobalt (center) bound to the aspartate ring in the closed state
of the TolC crystal structure (PDB 1TQQ). Carbon atoms for aspartate are in cyan.
but no antibacterial activity or potentiation of antibiotics was observed.71 The
compound has also been found to be toxic in E. coli.71
Further work sought to use computational methods combined with binding
assays and single-channel electrophysiology to identify new compounds that
would bind at the same site as hexamminecobalt with similar affinity.71 Several
compounds were found to bind at the same site with sub-micromolar affinity, but
none of the compounds potentiated antibiotics in vivo.71 Separate in vivo
experiments carried out independently from that work concluded that the
application of TolC as a target for efflux inhibition is not feasible in vivo.55 In
principle, inhibition of TolC would result in a decrease in the minimal inhibition
concentration (MIC) by preventing efflux. However, antibacterial assays show that
the MICs for different antibiotics are unchanged for a range of TolC concentrations
10-fold higher and lower than WT cells.55 The results imply that AcrAB in WT cells
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operates below the maximal capacity for substrate binding and extrusion; thus,
TolC does not limit drug efflux.

AcrA as a good drug target
The remaining plausible drug target for efflux inhibition of AcrAB-TolC is
AcrA. Unlike TolC, AcrA is expressed by the same operon as AcrB and AcrB is
dependent on AcrA for efflux.26, 72 We know from the recent cryo-EM structures
that the assembly of AcrAB-TolC agrees with the adaptor bridging model which
states that AcrB and TolC have no direct interactions and must be bridged by
AcrA.45 Inhibition of AcrA by a small molecule would conceivably disrupt the
assembly of AcrAB-TolC and prevent efflux. AcrA binds AcrB with sub-micromolar
affinity, but the affinity is dependent on the attachment of a lipid anchor to the Nterminus and the conformation of the MP domain.42 The MP domain interacts with
AcrB in the assembled complex.44 A mutation, G363C, in the MP domain
decreased the affinity of AcrA to AcrB.42 The disruption of binding affinity by G363C
and the lipid anchor could imply that conformational changes in the MP domain of
AcrA could disrupt AcrAB-TolC assembly. A protein inhibitor referred to as DARPin
binds AcrB and inhibits AcrB by displacing AcrA and thus disrupting assembly
(Figure 10).42 A small molecule that could bind AcrA and change the conformation
of the MP domain could conceivably prevent binding to AcrB, disrupt the assembly
of the pump, inhibit efflux, and ultimately potentiate the activity of antibiotics.
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Figure 10. The protein inhibitor DARPin (green) overlaps and interferes with the
binding of the AcrA dimer (blue and red) to AcrB in the assembled complex.
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Approach
Antibiotics were first discovered as metabolites produced by bacteria and
fungi in their natural environments that could then be used by humans to fight
infection.73 The metabolites are called natural products and were identified by a
technique referred to as the Waksman platform.73 The Waksman platform
identifies natural products such as streptomycin by testing soil samples for bacteria
which produce metabolites that can prevent the growth of pathogenic bacteria.73
The discovery of natural products as antibiotics ushered in a ‘golden age’ of
antibiotic discovery.73
However, since natural products were not intrinsically designed as drugs by
the process of natural selection, genetic elements that contain resistance genes
are prevalent in bacterial communities and can easily be transferred by horizontal
gene transfer; thus, resistance is easily attained.73 Another limitation is that natural
products are often large and can be chemically intractable to produce new analogs
by in vitro synthesis.73 Synthesis of new analogs requires mutation of bacteria to
produce new analogs that are subsequently purified and characterized in a laborintensive and costly process.73, 74 Moreover, most metabolites with antibacterial
properties have already been identified.73 On the other hand, libraries of synthetic
organic compounds such as the ZINC15 database contain millions of diverse
compounds that are easily amenable to in vitro synthesis.73, 75
Unlike natural products, synthetic organic molecules did not evolve by the
process of natural selection to overcome the heterogeneous outer membrane and
20

efflux pumps such as AcrAB-TolC in E. coli.73 Antibiotics act on multiple targets
such as DNA, ribosomes, and the cell wall that are intimately connected as a
mechanism of slowing down intrinsic resistance.73 If an antibiotic only interacted
with a single target, spontaneous mutation of the target would more easily render
the compound inactive. Interaction of multiple connected targets also allow for the
introduction of synthetic organic molecules (non-antibiotic) with proven therapeutic
activity such as compounds from the National Cancer Institute (NCI).73 The
application of a non-antibiotic and antibiotic compound by combination therapy
could help overcome the outer membrane and efflux in lieu of natural selection.
For example, loperamide is an anti-diarrheal drug that has also been shown to
destabilize the membrane potential (proton gradient) of bacteria and increase the
uptake of minocycline in Gram-negative bacteria.73 Combination therapy with a
non-antibiotic also reduces the required concentration of the antibiotic which can
further decrease the likelihood of resistance. 73
Here, we have performed high-throughput virtual screening of the NCI
Diversity V set containing 1,563 synthetic organic compounds and a filtered set of
the ZINC15 database containing 1,427 compounds to test for their ability to bind
AcrA. While experimental whole-cell screens identified previous EPIs MBX2319
and MC-207,110, neither have made it to clinical development.35, 62 Application of
multiple

target-based

and

whole

cell

high-throughput

experiments

by

GlaxoSmithKline failed to yield new antibiotics and cost $70 million over 7 years.76
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Application of our in-silico screening attempts to identify diverse compounds faster
and cheaper.
We propose that binding of a synthetic organic compound to AcrA could
inhibit efflux through two possible mechanisms before assembly of AcrAB-TolC:
1) Prevention of AcrA dimerization/oligomerization
2) Prevention of the MP domain from interaction with AcrB
by binding at predicted binding sites which will be validated using tryptophan
fluorescence spectroscopy and antibiotic susceptibility assays. AcrA has
previously been shown to be a monomer in solution in the absence of a lipid anchor
attached to the inner membrane in the assembled state.48 Homology models of the
AcrA monomer alone were built to screen the two databases of small molecules
for binding AcrA. A non-antibiotic compound that could bind AcrA would disrupt the
assembly. The two compounds would lead to a lower concentration of the antibiotic
required to decrease bacteria growth or kill the bacteria and act on different targets
helping to prevent resistance.
Finally, the database of 1,427 compounds from ZINC15 contains physicochemical descriptors for compounds that should overcome the outer membrane;
thus, computationally screened compounds that bind AcrA should conceivably
increase the diversity of chemically tractable compounds for further synthesis,
inhibit efflux, potentiate antibiotics, overcome the OM, and help prevent the spread
of multidrug resistance with superior efficiency to natural products and highthroughput whole cell experimental screens.
22

CHAPTER I
IDENTIFICATION OF NOVEL EFFLUX PUMP INHIBITORS THAT
INTERACT WITH ACRA BY COMPUTATIONAL METHODS
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Some results from this chapter were originally published in two manuscripts
of which I am a co-author. The citations for each manuscript are listed below.
•

•

Abdali, N.; Parks, J. M.; Haynes, K. M.; Chaney, J. L.; Green, A.
T.; Wolloscheck, D.; Walker, J. K.; Rybenkov, V. V.; Baudry, J.;
Smith, J. C.; Zgurskaya, H., Reviving Antibiotics: Efflux Pump
Inhibitors That Interact with AcrA, a Membrane Fusion Protein of
the AcrAB-TolC Multidrug Efflux Pump ACS Infectious Diseases
2016, 3, 89-98.
Haynes, K. M.; Abdali, N.; Jhawar, V.; Zgurskaya, H. I.; Parks, J.
M.; Green, A. T.; Baudry, J.; Rybenkov, V. V.; Smith, J. C.;
Walker, J. K., Identification and Structure-Activity Relationships of
Novel Compounds that Potentiate the Activities of Antibiotics in
Escherichia coli. Journal of Medicinal Chemistry 2017, 60 (14),
6205-6219.

In the Abdali et al. 2016 publication, Model A of AcrA were built by
Khushboo Bafna under the supervision of Jerry M. Parks (co-author) and Model B
was built by Jerome Baudry. Jerry and Khushboo carried out five nanosecond MD
simulations of each model. I then clustered each trajectory by their RMSD and
prepared them for ensemble docking by Jerry. I then analyzed the ensemble
docking and MD simulation results by calculating the enrichment profiles for each
conformation of both models to observe if using structures from MD helped to
improve the hit rate. I also calculated the RMSD of each domain relative to the
initial structure. I docked the NCI Diversity Set V to the AcrA crystal structure and
the homology models prior to MD simulation.
In the Haynes et al. 2017 publication, Figure 3 and the associated
description were compiled by me and the docking of the various analogs to the
hinge site of AcrA was completed by me. Analysis of the docking was completed
by Jerry and calculation of molecular descriptors of NSC60339 and the analogs
24

was completed by Sarah Cooper. Ryne Johnston helped me with organizing the
validation of the pKa calculations with ChemAxon Marvin.
All microbiology and biochemical experiments were carried out by Helen
Zgurskaya’s Lab at the University of Oklahoma and John Walker’s lab at St. Louis
University School of Medicine.

Overview
Structure-based drug design is a part of computer-aided drug design that
seeks to accelerate the discovery of new drug candidates for clinical
development.77 The concept requires knowledge of the atomic structure of the
intended drug target such as AcrA. However, an experimentally determined
structure of AcrA is incomplete.78 The MP domain, which plays a key role in the
assembly of AcrAB-TolC, is missing in the structure. Thus, we built comparative
(homology) models of AcrA from similar proteins closely aligned in sequence,
structure, and function. We then relaxed these models using MD simulation and
extracted conformations by RMSD clustering of the trajectories. The conformations
were then docked to compounds in the NCI Diversity V to identify new candidates
that bind AcrA, inhibit efflux, and potentiate antibiotics. Multiple conformations
were used to mimic a conformational selection mechanism of ligand binding.
Multiple predicted inhibitors were successfully validated by experimental methods,
but only one compound, NSC60339 was found to change the structure of AcrA in
vivo and thus disrupt the assembly of AcrAB-TolC. A structure-activity relationship
(SAR) was subsequently carried out for NSC60339. In this chapter, I not only
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discuss the identification of new inhibitors that interact with AcrA and the SAR of
NSC60339, but also review models of ligand binding, protein structure prediction,
MD simulations, and molecular docking.

Models of ligand binding
Part of how ligands interact with their protein partners is by shape.79, 80 A
ligand that binds a protein has a complementary shape analogous to a lock and a
key.81 This ‘lock-and-key’ mode assumed an overly simplistic view of protein-ligand
binding. The model assumes that proteins and ligands are static entities. In fact,
proteins are dynamic entities that fold into their native three-dimensional structures
by a free energy landscape.82 A free energy is the probability of a specific
conformation; in this case, a protein. The lower the free energy, the higher the
probability.83 In 1968, Cyrus Leventhal proposed a thought experiment that it would
take a single protein longer than the age of the universe to sample all the possible
conformations to find its native structure.84, 85 The conception of a free energy
landscape resolved this paradox by asserting that proteins fold by favoring
conformations of lower free energy.86 The folded, native, state is reached when a
protein reaches a low energy state (Figure 11). A free energy landscape is
dynamic and implies that a protein can change conformation when binding a
ligand.79 The binding of a ligand induces a conformational change in a protein to a
lower free energy to enhance the interactions with the ligand.87 The model is

26

Figure 11. Funnel free energy landscape. The lowest energy state is denoted by
the letter N which stands for native state. Landscape was created by the Ken Dill
Group under a Creative Commons Attribution 4.0 international license.
referred to as the induced fit model of ligand binding. However, it is now known
that proteins often do not exist as a single lowest energy conformation. Their free
energy landscapes are far more complex; thus, they exist as an ensemble of
lowest energy conformations prior to ligand binding.82 The addition of a ligand then
selects for a conformation of the protein from the ensemble prior to binding and is
referred to as conformational selection.79 All protein structure prediction and
modeling algorithms such as MODELLER and MOE used here, to the best of my
knowledge, utilize the assumption of a free energy landscape to find the best
structures.88 In addition, docking algorithms that predict protein-ligand binding
poses that include ligand and receptor flexibility often follow the induced fit or
conformational selection model of ligand binding. 89, 90

Protein structure prediction
The number of protein sequences available is roughly 700 times the number
of protein structures deposited on the Protein Data Bank (PDB).91 Given this
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information in the genomics era, accurate structural modeling could enable the
identification of new drug targets, new drugs, and accelerate structure-based drug
design.91,

92

In theory, a protein structure should be able to successfully be

predicted from its sequence alone and is referred as de novo modeling.93 Protein
modeling de novo requires a potential energy function to calculate the energetics
of each possible conformation from a protein’s sequence.93 A potential energy
function often consists of terms to estimate the van der waals (VDW) and
electrostatic interactions (Coulombic), hydrogen bonding, and desolvation.94,

95

Given proper parameters for the energy function and sampling of the possible
conformations, an estimate of the energy landscape could be reconstructed and
the lowest energy structure identified as the best prediction.95 However, this
approach has only been successful, to the best of our knowledge, for small singledomain proteins.93 Larger proteins with multiple domains and/or subunits typically
require the use of experimental or large-scale sequence data to construct an
accurate model. 95-97
Protein structural modeling algorithms that rely on potential energy
functions and experimental data such as disulfide cross-links as restraints to guide
the folding process are referred to as knowledge-based algorithms.95 These
approaches are useful when experimental data is available and when no similar
protein sequences with associated structures are available. When sequence data
is abundant, a commonly used method for protein structural modeling is referred
to as comparative (homology) modeling. Homology modeling predicts the three28

dimensional structure of a protein sequence by threading the structure of a similar
sequence that has a known protein structure.91 This type of modeling assumes
that changes in a protein structure occur much slowly than changes in a protein’s
sequence.91 In other words, differences in protein sequences will still yield very
similar structures.
In this work, we utilized homology modeling to construct models of AcrA that
include the missing membrane-proximal domain (MP) from the crystal structure.
To build a homology model, the first step is to identify a suitable template. A
suitable template is a known protein structure determined from X-ray
crystallography or nuclear magnetic resonance (NMR) with a sequence identity of
about 25% compared to the sequence that will be modeled.91,

92

A suitable

template should also have secondary structure that agrees with the predicted
secondary structure of the sequence. For one of the models (Model A), we used
the HHPred web server to identify an adequate template based on sequence
identity and secondary structure and then the program MODELLER to build the
model.98, 99 For the second model (Model B), we used an algorithm implemented
in the commercial software MOE.100 With MOE, we chose the crystal structure of
ZneB (PDB 3LNN) as a suitable template for one of the models.101 ZneB is part of
a tripartite assembly referred to as ZneCAB that spans the bacterial envelope of
Cupriavidus metallidurans similar to AcrAB-TolC in E. coli.31, 101 It is also part of
the membrane fusion protein (MFP) family like AcrA.101 ZneCAB is an efflux
transporter that is specific for the export of zinc ions.101 The function of ZneB as
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an MFP is analogous to AcrA and has a sequence identity of 27% (Figure 12).
The structure also matches AcrA by consisting of an a-helical hairpin, lipoyl, bbarrel, and MP domain (Figure 13). With HHPred, ZneB was also one of the top
choices for a template, but we chose CusB. CusB is also part of a tripartite complex
referred to as CusCAB that is responsible for the efflux of heavy metals (silver and
copper) and some hydrophilic antibiotics.26 CusB is an MFP that forms a hexameric
funnel and engages in an open-close transition.26, 102 However, while the function
of CusB is similar to AcrA, the sequence identity is only 20%; thus, we built the
model with an additional template. The additional template was the partial crystal
structure of AcrA that lacks the MP domain (Figure 13). The addition of multiple
templates in homology modeling can help build more accurate models with low
sequence identity.103 Nevertheless, the sequence identity of the MP domain of
CusB and AcrA was only 21% (Figure 14). The sequence identity between the MP
domains of AcrA and ZneB were 27% (Figure 14). While both models contain low
sequence identity, they are derived from templates that are functionally similar to
AcrA. The functional similarities of CusB and ZneB may explain why the application
of both models still led to identification of new efflux pump inhibitors for AcrA.
Another possibility could be the incorporation of multiple conformations obtained
from MD simulation that will be discussed later.
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Figure 12. Multiple sequence alignment of the AcrA sequence (NP_414996, K-12
MG1655) with the sequences from the X-ray crystal structures of CusB (PDB
3NE5) and ZneB (PDB 3LNN). The sequence identity between AcrA and CusB
and ZneB is 20% and 27%, respectively.

A.

B.

C.

Figure 13. (A) X-ray crystal structure of AcrA (PDB 2F1M) with the missing MP
domain. (B) Homology model (Model A) built from CusB and AcrA templates with
MODELLER. (C) Homology model (Model B) built from ZneB template with MOE.

Figure 14. Multiple sequence alignment of the full-length AcrA sequence with the
sequences extracted from the MP domains of the X-ray crystal structures of CusB
and ZneB. The sequence identity between the MP domains between AcrA and
CusB are 21%. The sequence identity between AcrA and ZneB is 27%. The
sequence for the MP domain of AcrA was obtained from a later homology model
built using a separate template.
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Molecular dynamics simulations
Molecular dynamics (MD) simulations is a computational method that can
be implemented to optimize initial homology models.104 Loops and side chains are
conformationally more variable than main chain, a-helix, and b-barrel atoms; thus,
hindering the accuracy of the initial homology models.105, 106 Ramachandran plots
can be used to visually assess secondary structure elements by the f,y angles of
the protein backbone and validate the accuracy of a homology model.91 Angles
that do not correspond to a specific secondary structure may exist in disallowed
regions and can indicate the presence of a steric clash in the model.105
Ramachandran plots of the Model B mentioned above reveal a decrease in the
number of f,y angles in the disallowed regions after a short MD simulation
trajectory (Figure 15). MD simulation refined Model B and eliminated some steric
clashes between atoms. Nevertheless, some disallowed angles remain in Model
B after MD simulation in contrast to Model A which revealed no disallowed angles
even before MD simulation (Figure 15). Model A may be a structurally more
reliable model of AcrA than Model B despite having a lower sequence identity. The
combination of multiple templates may contribute to the improved modeling. Model
B also contains an extended unstructured loop at the b-barrel domain that is absent
in Model A (Figure 13).
MD simulation propagates the dynamics of a protein by integration of
Newton ‘s second law of motion, which states that:
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Figure 15. Ramachandran plots of Model A built with a multi-template approach
using AcrA and CusB crystal structures and Model B built using a single-template
approach using the ZneB crystal structure. Model B contains numerous structural
outliers outside of the allowed regions; thus, multiple steric clashes exist. Five
nanoseconds of MD simulations resolve some of the clashes, but some remain.
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𝐹# = 𝑚# 𝑎#
where Fi, mi, and ai are the mass, net force, and acceleration of atom i107 in the
protein.108 The acceleration of atom i can be derived by the second derivative of
the position of the ith atom with respect to time.
𝑎# =

𝜕 ( 𝑟# 𝑡
𝜕𝑡 (

Integration of the acceleration can then yield the positions and velocities of each
atom at a defined time interval. Time in MD simulations is discretized by
femtosecond units referred to as time steps. Thus, positions and velocities can be
updated by various integrators such as the leapfrog algorithm reported below.109,
110,111

1
1
𝑣 𝑡 + 𝛿𝑡 = 𝑣 𝑡 − 𝛿𝑡 + 𝑎(𝑡)𝛿𝑡
2
2
𝑟 𝑡 + 𝛿𝑡 = 𝑟 𝑡 + 𝑣 𝑡 +

1
𝛿𝑡 𝛿𝑡
2

where the velocities are calculated first from the acceleration of the atom which is
taken from the net force. Initial velocities are estimated from a Maxwell-Boltzmann
distribution given a target temperature of the simulation.109 The velocities then play
leapfrog to calculate the positions of each atom at a defined timestep. The net
force experienced by each atom is derived by the negative gradient of the potential
energy
𝐹# = −∇𝑈#
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where U is the potential energy of the ith atom. The potential energy is expressed
as a function that encompasses all the bonded and nonbonded components for
each atom.94, 107
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The bonded and nonbonded terms encompass the essence of a molecular
mechanics (MM) potential energy function or force field. MM differs from quantum
mechanics (QM) by utilizing the Born-Oppenheimer approximation.112 The BornOppenheimer approximates states all the degrees of freedom of the electrons of
each atom are relaxed, i.e. in their lowest energy (ground) state configurations.
Thus, MD simulations cannot simulate chemical reactions.112 The bonded terms
include 1-2 interactions (bonds), 1-3 interactions (angles), and 1-4 interactions
(dihedrals) (Figure 16). The bonds and angle terms are represented by a harmonic
potential (Figure 17) where the equilibrium values (b0,q0) and force constants (K0,
Kq) are estimated by a best-fit between ab initio quantum mechanical target data
and molecular mechanics or through available experimental data (IR, X-ray
diffraction, Raman).94, 113 The dihedral term is represented by a cosine function
where n represents the number of minima along the dihedral potential energy
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Figure 16. Bonded terms in an MD simulation: bond stretching, angle bending,
and dihedral angles. Bonded terms can be characterized as 1-2, 1-3, and 1-4
interactions based on the number of atoms included.

A

B
Single bond stretching

Dihedral potential energy as a function of
n

0
0.5

1

1.5

2

2.5

60

120

180
n=3

240
n=2

300

360

n=1

Figure 17. Bonded potential energy profiles (A) Representative harmonic potential
bond which has a bond length of 1.54 A. (B) Potential energy profile of a dihedral
angle represented by molecular mechanics. The term n represents the number of
minima in the profile that can be used to fit QM target data.
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surface (Figure 17). The nonbonded terms are modeled by a Coulombic and 6-12
Lennard-Jones (L-J) potential. Nonbonded interactions are divided into two
subcategories: electrostatic interactions between two charged atoms and van der
waals (VDW) interactions.94 Electrostatic interactions are distance and dielectric
dependent. In contrast, VDW interactions are only distance dependent.114 The
medium or solvent where two charges (qiqj) interact can be expressed as a
constant is referred to as the dielectric constant.94 For the MD simulations
performed of our two homology models and for most proteins, water is the typical
solvent and has a dielectric constant of 78.5, but a common water model used in
MD simulation overestimates the dielectric constant by about 5-20% (82-96).115
The force field and water model used in the short MD simulation trajectories
of our two homology models are referred to as CHARMM22 and TIP3P.69 TIP3P
(three-site intermolecular potential) is the most commonly used water model in MD
simulation due to computational efficiency.116 The water model only considers
noncovalent interactions between the oxygen and two hydrogen atoms.115 The
interactions and hence polarizability of the lone pairs attached to the oxygen atom
are ignored.117 The negation of polarizability of the oxygen atom in water partially
contributes to the incorrect dielectric constant for water in MD simulation.115 Other
reasons include the truncation of VDW and coulombic interactions and the
estimation of fixed partial charges from quantum mechanical electrostatic
potentials.118, 119 VDW interactions between two atoms only favorably interact at
close enough distances triggered by the effect of an induced dipole.105 At long
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enough distances, the potential energy for a VDW interaction is effectively 0
kcal/mol (Figure 18). Thus, MD simulation can use cut-off methods to stop
calculating VDW energies past a certain distance. The standard cut-off for MD
simulation with the CHARMM force field is 12 Å.120 However, inclusion of a method
referred to as Ewald summation for electrostatics and long-range corrections for
VDW energies have been shown to improve the value of the dielectric constant
and/or other experimental observables at a greater computational cost.121 Ewald
summation must be performed for accurate electrostatics since the potential
energies decay at 1/r and thus a short cut-off produces artifacts (Figure 18).122
More sophisticated water models such as TIP4P and TIP5P and polarizable force
fields such as the CHARMM Drude polarizable force field have also been
implemented with improved values of the dielectric constant at the expense of
increased computational requirements.117 Nevertheless, despite the systematic
failure of the TIP3P water model and nonpolarizable CHARMM force field to
accurately reproduce the dielectric constant, both can still reproduce other
experimental observables such as heat of vaporization and solvation free
energies.114, 123 Accurate thermodynamic estimates may be due in part to error
cancellation from computing energy differences, but the estimates allow us to
make a successful trade-off between theoretical rigor and computational
efficiency. The MD simulations with the non-polarizable force field and water model
not only optimized our homology models, but also showed their interdomain
flexibility.
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Figure 18. Nonbonded energy profiles in an MD simulation (A) Lennard-Jones 612 potential with an attractive energy well and a repulsive component. (B)
Coulombic potential which decays at a rate of 1/r.
MD simulation can be used to assess the flexibility of the models. A model
that is more flexible over short timescales may indicate less stability (greater
tendency to unfold) and thus is a less suitable model for the intended sequence.
The methodology is particularly important in the evaluation of potential mutants for
site-directed mutagenesis.124 A common metric used to assess flexibility in MD
simulation is the root-mean-square-deviation (RMSD)

𝑅𝑀𝑆𝐷 =

1
𝑁

b

𝑑#

(

#cQ

where di is the distance between a given atom in a structure and the equivalent
atom in a reference structure such as the first frame of the trajectory.125 Typically,
only the backbone or Ca atoms are chosen. The greater the RMSD, the more
flexible the model over the timescale of the simulation.125 The model built with
MOE referred to as Model B had a backbone RMSD of approximately 9 Å over the
timescale of the simulation (Figure 19). The model chosen with HHPred and
MODELLER referred to as Model A had a backbone RMSD of 6 Å indicating
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Model A

Model B

Figure 19. Backbone RMSD of AcrA models and their individual domains over MD
trajectories measured relative to the initial coordinates of model A (left) and model
B (right).
slightly less flexibility over the short simulation time (Figure 19). For both models,
the interdomain flexibility was in decreasing order: MP domain, b-barrel, a-helical
hairpin, and lipoyl (Figure 19). The decreased flexibility of Model A compared to
Model B could be due to the use of a multiple templates with one of the templates
being the partial crystal structure of AcrA. Greater flexibility in Model B is also in
agreement with the poor structural representation observed in the Ramachandran
plots (Figure 15). The increased flexibility of the MP domain in both models would
be expected since the domain was not captured by X-ray diffraction.78 Also, as
discussed previously, conformational changes in the MP domain are known to
affect the assembly and stability of the assembled complex.42
Backbone RMSD is not only a metric that can be used to assess flexibility,
but can be also applied as a clustering algorithm that selects frames from the MD
trajectory to construct an optimal ensemble of configurations for each model.89, 126
We used the clustering tool, g_cluster, included with GROMACS 4.6.5 to group all
the frames into specific clusters within a cutoff of 2.5 Å and then selected the
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centroid structure from each cluster as a conformation in the ensemble.127 For
Model A and B, 12 and 15 conformations were selected, respectively. These
conformations were then used as the basis for a form of molecular docking referred
to as ensemble-based virtual screening to identify new efflux pump inhibitors for
AcrA.

Molecular docking
Molecular docking is used to predict the binding poses of new ligands to
specific target such as a protein.107 Docking is useful for distinguishing between
binders and non-binders; thus, helping to infer structure-activity relationships
(SAR) and constructing a priority list of compounds to be tested for experimental
validation.126 A docking algorithm consists of two components: sampling and
scoring.107 The most commonly used docking software is the program AutoDock
likely due to its speed, ease of use, and open-source platform.128 Also, when
multiple docking algorithms are compared to experimental data, AutoDock Vina
consistently appears as one of the best algorithms.129 AutoDock Vina was
significantly optimized from previous versions of AutoDock and was found to have
improved agreement with crystallographic poses and experimental binding
affinities.130
Vina begins from a random initial conformation and position in a pre-defined
grid or search space.107, 131 The search space can be an experimentally known
binding site or predicted by various algorithms.130 A single docking run consists of
a series of sequential steps that consist of a random perturbation of the ligand
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position. The precise number of steps is determined on-the-fly by Vina depending
on the size of the grid and the flexibility of the ligand. Larger grids and more flexible
ligands will require more steps (i.e. more positions to perturb).130 Each step is then
assigned a score, an estimate of the protein-ligand binding free energy, and the
gradient of the score with respect to the position is computed until no change in
the gradient is detected.107 A gradient of 0 or close to zero would indicate that the
resulting pose is at a minimum on the free energy landscape.112 The pose is
accepted in a protocol analogous to a metropolis Monte Carlo (MC) algorithm.130
If the energy of the pose is improved (lower) from the previously accepted pose,
then the new pose is accepted. If not, then the pose is accepted per a probability
set by the metropolis criterion. For the sake of simplicity, the original
implementation of the metropolis criterion is shown below:
𝑃𝑟𝑜𝑏 ~ exp

− 𝐸Q − 𝐸k
𝑘m 𝑇

where E1 and E0 and the new and previous energies, respectively, kB is the
Boltzmann constant, and T is the temperature.107 Vina uses a stochastic global
optimization protocol that can be considered a variant of the metropolis criterion
and MC method.130, 132 The use of a metropolis MC algorithm helps to ensure that
accepted poses are not trapped in a local minimum; thus, only global minima are
accepted.133 The resulting accepted poses are then ranked for a given ligand. The
number of docking runs that Vina implements can be tuned by the user through a
parameter referred to as the exhaustiveness.134 The default exhaustiveness is 8
and was used for all docking calculations described in this chapter.134 Larger boxes
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and more flexible ligands likely require a higher exhaustiveness at the expense of
more computational time providing a hindrance for screening large databases of
compounds. 130
The scores that define the estimated free energies of each pose of the
ligand bound to the protein in Vina are based on empirical weights to estimate
intermolecular (protein and ligand) and intramolecular (ligand and protein alone)
contributions of the estimated binding free energy of the predicted pose.130, 135 The
estimated weights consist of terms that define the shape of a given pose in the
binding site, hydrophobic interactions, desolvation, and hydrogen bonding.130 Vina
is thus based on the concept that a protein-ligand complex should form a
complementary shape. For example, a pose that results in a steric clash with no
hydrophobic or hydrogen bonding interaction may have an unfavorable score and
likely not be accepted by the Vina algorithm. The empirical weights were
determined using linear regression of the PDBBind training set containing 190
protein-ligand complexes with experimentally known binding affinities. 130
In contrast to Vina, a previous implementation of AutoDock used an MM
potential energy function that consisted of a Coulombic term for electrostatics, an
L-J 6-12 potential for VDW interactions, a separate 6-12 potential to specifically
describe hydrogen bonding, and a desolvation term.135 The sampling algorithm
was also not related to MC, but referred to as a Lamarckian genetic algorithm.131
It is interesting to note that the introduction of a non-physics based scoring function
led to improved agreement with experimental data.130 This trend is also true for
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many other empirical docking algorithms and may be indicative of a move that
could pave the way for more machine learning/deep learning algorithms to predict
protein-ligand binding affinities.129
Vina always incorporates the flexibility of the ligand, but flexibility of side
chains within the chosen binding site or search space can be selected by the
user.130 It is estimated that docking algorithms predict the incorrect binding pose
for approximately 50-70% of all ligands when only a single protein receptor
conformation is considered.136 Inclusion of side chain flexibility increases the
computational cost which can hinder large-scale screening of chemical databases
and requires knowledge of the binding site.126 In our case for AcrA, we predicted
two possible binding sites that will be discussed below to dock 1,563 compounds
from the NCI Diversity Set V; thus, an alternative method to incorporate receptor
flexibility was needed.
An alternative method is referred to as ensemble docking or the relaxed
complex scheme.137 The method incorporates receptor flexibility within AutoDock
Vina by docking each ligand to multiple conformations obtained from RMSD
clustering of a short MD simulation trajectory of the protein.138 Conformations
extracted from a 2 ns simulation have been shown to identify new ligands and a
novel binding site not observed in crystal structures.139 A quantitative metric to
assess the impact of multiple conformations on docking success is called
enrichment.126 The enrichment is defined by the following equation:
𝐸𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 =

# 𝑜𝑓 𝑏𝑖𝑛𝑑𝑒𝑟𝑠 𝑖𝑛 𝑎 𝑠𝑢𝑏𝑠𝑒𝑡
𝑡𝑜𝑡𝑎𝑙 # 𝑜𝑓 𝑙𝑖𝑔𝑎𝑛𝑑𝑠 𝑖𝑛 𝑠𝑢𝑏𝑠𝑒𝑡
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where a subset is defined as a part of the total screening database that is ranked
according to the scoring function.126 The inclusion of multiple conformations allows
for a sampling of local (side chain) conformations and thus mimic a conformational
selection and/induced fit model of ligand binding.126, 140 A parallelized version of
AutoDock Vina referred to as VinaMPI was constructed to parallelize the ensemble
docking of multiple conformations to a database of potential ligands on petascale
supercomputers.138 We implemented VinaMPI in all docking calculations
presented in this chapter.
We docked the 1,563 compounds from the NCI Diversity Set V because the
compounds are freely available for experimental testing and previous work has
been involved in repurposing FDA-approved drugs such as chemotherapeutics as
new antibiotics.141 We identified two potential binding sites as search spaces for
docking runs referred to as the hinge and MP sites (Figure 20). The latter has
been discussed previously to play a role in the assembly of the pump and in the
interactions between AcrA and AcrB, but the functional relevance of the former,
the hinge site, has been unclear.42 Previous MD simulations of a close homolog of
AcrA, MexA in P. aeruginosa, has revealed a hinge-bending motion between the
lipoyl and a-helical hairpin domain.125 We showed that the residue E67 when
mutated to arginine and alanine decreases the MIC of novobiocin and
erythromycin, substrates of AcrAB-TolC, compared to the WT indicative that the
efflux of both antibiotics has been impaired (Figure 21). A smaller search space
was used for the hinge site due to the functional relevance.
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A

B

Figure 20. (A) Docking search space with dimensions 25 Å x 25 Å x 25 Å for the
hinge site. The center of the box is shown as red spheres and represents the Ca
atom of Ser138. (B) Docking search space with dimensions 45 Å x 45 Å x 45 Å
for the MP site. The center of the box is shown as red spheres and represents the
Ca atom of Gln270. The a-helical hairpin, lipoyl, b-barrel, and MP domains are
shown in red, blue, orange, and green, respectively.
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Figure 21. (A) Conformations extracted from MD simulation of Model A and
overlaid with the X-ray crystal structure (red) of AcrA to reveal a hinge-bending
motion at the lipoyl-hairpin interface. (B) Residues located at the hinge site. (C)
Susceptibility assay to novobiocin with WT AcrA and mutants at the hinge site
reveal the functional relevance of the site.
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In contrast, the entire MP domain was searched centered just above the interface
between the b-barrel and MP domain and covered the entire domain (Figure 20).
The precise binding site at the MP domain will be explored in the following chapter.
Docking to both sites identified 11 compounds that potentiate novobiocin
and erythromycin (Table 1). The application of multiple conformations in our virtual
screening accelerated the identification of the 11 compounds. The top 1-2% of
compounds in the ranked database have a ~10% increase, enrichment, in the
identification of the 11 compounds when one or more of the conformations from
MD are used for the hinge and MP sites in contrast to the initial homology models
and the crystal structure (Figure 22-23). Enrichment reveals that ensemble-based
virtual screening was helpful in the identification of new compounds with efflux
pump inhibitor (EPI) characteristics.
To determine if the 11 compounds have EPI-like characteristics and
interacts with AcrA, they should ideally possess the seven qualities mentioned
previously and bind with AcrA. Seven out of 11 compounds were determined to
bind AcrA by surface plasmon resonance (SPR) (Figure 24).

Table 1. Minimal Inhibitory Concentrations and Potentiating Activities of
Top Hits
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Figure 22. Enrichment profile for ensemble-based virtual screening at the hinge
site to AcrA crystal structure (red), homology models (black), and each
configuration from MD simulation (dotted).
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Figure 23. Enrichment profile for ensemble-based virtual screening at the MP site
to the homology models (black) and each configuration from MD simulation
(dotted).
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Figure 24. Seven compounds that bind AcrA with EPI-like characteristics.
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As a reminder, the characteristics of an EPI are as follows.61, 62
i)
ii)
iii)
iv)
v)
vi)
vii)

bypass the OM permeability barrier
potentiate efflux pump substrates
No potentiation of substrates in DTolC cells
Inhibits efflux and thus increases the uptake of
substrates in the cell
No disturbance of proton gradient across the inner
membrane
No antibacterial activity
No potentiation of non-substrates.

None of the 7 compounds can bypass the OM permeability barrier (Table 1). The
MIC values of the remaining compound are lower in WT-Pore cells compared to
WT indicating greater susceptibility in WT-pore cells (Table 1). WT-pore cells
contain 2.4 nm pores in the OM that increase the porosity and thus allow a more
diverse array of compounds to enter the OM and interact with periplasmic targets
such as AcrA.142 Once a compound is identified to potentiate and bind AcrA,
analogs can later be constructed to improve accumulation in WT cells. Six of the
7 compounds potentiate both efflux pump substrates novobiocin and erythromycin
and all 7 lack potentiation in efflux-deficient, DTolC, cells (Table 1). Potentiation is
monitored by the minimal potentiating concentration (MPCn) of the EPI that causes
the minimal inhibitory concentration (MIC) of the antibiotic to decrease at least nfold. In our case, n is 4. The lower the MPC4, the greater the potency. As an
example, the lowest MPC4 value for an EPI of AcrAB-TolC is near zero at 0.05
µM.61 NSC354844 lacks potentiation of erythromycin (Table 1). All the compounds
contain very weak intrinsic antibacterial activity with MIC values less than 200 µM
and disruption of the proton gradient was not assessed (Table 1). The higher the
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MIC value, the weaker the antibacterial activity. A MIC value indicated as “>200”
as effectively no antibacterial activity. Potentiation of non-substrates was not
assessed likely because of the compounds’ intrinsic antibacterial activity. The
compounds likely act on other targets to inhibit the growth of E. coli. All 7
compounds except NSC354844 and NSC207895 are substrates of AcrAB-TolC
which implies that they also bind AcrB and are subject to efflux (Table 1). The MIC
values decrease in WT DTolC-Pore cells (Table 1). The ability to function as
substrates for 5 of the 7 compounds may indicate that these compounds interact
with other transporters in E. coli such as AcrDA-TolC and AcrEF-TolC. Four of the
seven compounds: NSC60339, NSC227186, NSC33353, and NSC305798 were
chosen for further characterization to test their ability to increase the accumulation
of Hoechst H33342 probe, an AcrAB-TolC substrate, their spectrum of activity in
other Gram-negative bacteria, and their mechanisms of action. The remaining
three compounds were excluded because they were ranked lower in the docking
calculations for at least one site (Table 2). However, all three compounds could be
re-examined to further elucidate their mechanism of action and efflux inhibition
despite being low in the ranked database for at least one of the sites. NSC207895
binds AcrA, has sub-micromolar MPC4 values for novobiocin and erythromycin,
and is not a substrate of AcrAB-TolC (Table 1). NSC354844 is also a nonsubstrate of AcrAB-TolC and could be of interest despite lacking potentiation in
erythromycin (Table 1). NSC50651 has the same EPI-like characteristics and
shortcomings as the four chosen inhibitors, but has the sub-micromolar MPC4
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Table 2. Percentage rank of top hits from virtual screening of hinge and MP
sites

values for novobiocin and erythromycin (Table 1). Nevertheless, all three
compounds have greater intrinsic antibacterial activity than the four chosen for
further characterization diminishing their ability to function as unique EPIs.

Novel mechanism of action for NSC60339
Three of the four chosen inhibitors successfully satisfy criterion number 4
by increasing accumulation and thus inhibiting efflux as measured by fluorescence
of the AcrAB-TolC substrate and fluorescent probe Hoechst H33342. NSC227186
also known as clorobiocin is intrinsically fluorescent and thus could not accurately
be tested. Since NSC227186 is also a substrate, it may be a competitive inhibitor
for AcrAB-TolC. The binding of AcrA may not be the primary mechanism of action
for NSC227186. For NSC60339, the fluorescence of Hoechst H33342 increases
and plateaus at 3X the initial rate of uptake in the absence of the inhibitor in WTpore cells (Figure 25). WT-pore contains a functional AcrAB-TolC complex; thus,
fluorescence should only slowly increase in contrast to DTolC cells. DTolC cells
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NSC60339

NSC33353

NSC305798

Figure 25. Hoechst H33342 fluorescence accumulation and efflux inhibition
assays for NSC60339, NSC33353, and NSC305798 in WT-Pore and DTolC cells.
show no change in initial rate of uptake for NSC60339 and NSC305798 as
fluorescence increases equally as rapid with and without the inhibitor (Figure 25).
Both NSC33353 and NSC30598 in WT-Pore cells increase fluorescence linearly
in contrast to NSC60339 and the slope of Hoechst H33342 uptake in DTolC cells
is positive for NSC33353 (Figure 25). If fluorescence is increasing in the presence
of NSC33353 in DTolC cells, it likely means that NSC33353 has additional
interactions in bacteria (Figure 25). In fact, when we compare the spectrum of
activity of NSC33353 and NSC60339 across five different bacteria: Escherichia
coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacter cloacae,
and Klebsiella pneumoniae, we see that NSC33353 potentiates novobiocin and
erythromycin in all of them except Pseudomonas aeruginosa (Table 3). On the
other hand, inhibition by NSC60339 appears to be specific for E. coli (Table 3).
The MPC4 values for NSC60339 are higher than previously shown due to OM
impermeability.
NSC60339 is also the only discovered compound to change the structure
of AcrA in vivo in the assembled complex. Proteolysis by trypsin cleaves the C54

Table 3. Spectrum of activity for NSC60339 and NSC33353
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terminus of lysine and arginine residues when they are exposed to water. In the
absence of NSC33353, NSC305798, NSC227186, and NSC60339, two proteolytic
fragments are present (Figure 26). The two fragments are K46-K396 which
represents the complete protein and K46-R296 which represents the a-helical
hairpin, lipoyl, and b-barrel domains. In the presence of NSC60339, a new
fragment, K46-K346, is present. K346 is in the MP domain (Figure 26). The
binding of NSC60339 to AcrA changes the structure of the MP domain that
exposes K346 to water for cleavage by trypsin. Previous EPIs MC-207,110 and
MBX2319 do not change the structure of AcrA (Figure 26).
NSC60339 is also the only discovered compound to change the structure
of AcrA in vivo in the assembled complex. Proteolysis by trypsin cleaves the Cterminus of lysine and arginine residues when they are exposed to water. In the
absence of NSC33353, NSC305798, NSC227186, and NSC60339, two proteolytic
fragments are present (Figure 26). The two fragments are K46-K396 which
represents the complete protein and K46-R296 which represents the a-helical
hairpin, lipoyl, and b-barrel domains. In the presence of NSC60339, a new
fragment, K46-K346, is present. K346 is in the MP domain (Figure 26). The
binding of NSC60339 to AcrA changes the structure of the MP domain. Previous
EPIs MC-207,110 and MBX2319 do not change the structure of AcrA (Figure 26).

Structure-activity relationship of NSC60339
To improve the potentiation of AcrAB-TolC substrates such as novobiocin by an
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Figure 26. In vivo proteolysis with trypsin for MBX2319 (A), MC-207,110 (B),
NSC305798 (C), NSC33353 (D), NSC60339 (E), and NSC227186 (F) revealed
that NSC60339 has a novel mechanism of action.
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EPI, a structure-activity relationship (SAR) needs to be derived. A SAR is the
identification of correlations between different parts of a drug’s structure with
biological activity.65 For NSC60339, we compared the modification of the structure
with MPC4 values for novobiocin to assess the impact of the structure on the
potentiation of substrates. We began our SAR by examining the best-scoring
docking pose for NSC60339 to the hinge site of AcrA. Docking suggested that the
dihydroimidazoline ring could form interactions with the backbone carbonyls of
A172 and I65 (Figure 27). The chloro group was also found to oriented towards
V176, a hydrophobic residue; thus, modification of this group may impact
potentiation (Figure 27). Moreover, we predicted the pKa of the sp2 nitrogen to be
9.84 for the dihydroimidazoline ring acting as a meta substituent to the central ring
and 9.24 for the same nitrogen as the ortho substituent to the central ring with the
software ChemAxon Marvin 16.7.11 (Figure 28).143 The pKa is estimated from the
acid dissociation constant, shown below, and is a measure of a functional group’s
tendency to donate or accept a proton.105
pK z = − log 𝐾G
𝐾G =

𝐻~ 𝐴€
𝐻𝐴

𝐴€ is the concentration of the conjugate base of the dissociated species in solution.
The Henderson-Hasselbach equation states,
𝑝𝐻 = 𝑝𝐾G + log

𝐴€
𝐻𝐴

that when the pH of the solution is less than the pKa of the ionizable atom, the atom
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Figure 27. Best-scoring docking pose of NSC60339 to AcrA at the hinge site.
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Figure 28. Predicted and experimental pKa values for 1,2,4 triazole and 4-methyl1,2,4 triazole. Predicted pKa values for the dihydroimidiazoline rings of NSC60339.
All predictions were carried out with ChemAxon Marvin 16.7.11.
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will be protonated.105 Conversely, when the pH is greater than the pKa, the atom
will be deprotonated. The pH is a measure of the concentration of dissociated
protons in solution:
𝑝𝐻 = − log 𝐻~
thus, a solution with a low pH is more effective at donating protons to molecules
such as NSC60339.105 The predicted pKa values for the dihydroimidazoline are
greater than a standard pH solution of 7; thus, the dominant chemical species of
NSC60339 should be di-cationic and be identified as dihydroimidazolium rings. To
validate our predictions, we predicted the pKa of two similar rings with known
experimental pKa values: 1,2,4 triazole and 4-methyl-1,2,4 triazole (Figure 28).
1,2,4 triazole has an experimental pKa values of the nitrogens of 2.2 and
10.3(Figure 28).144 The predicted pKa values by ChemAxon Marvin are 2.46 and
10.39, respectively. 4-methyl-1,2,4 triazole has an experimental pKa of 3.4 and a
predicted pKa of 2.12 (Figure 28).144 The predicted values are close to the known
experimental values; thus, we should be able to trust with reasonable accuracy
that NSC60339 is di-cationic in solution.
As mentioned previously, the docking pose of NSC60339 at the hinge site
reveals hydrogen bonding interactions with the dihydroimidazolium rings (Figure
27). Complete replacement of the dihydroimidazolium rings with groups such as
hydoxymethyl, cyano, and sulfonic acid resulted in a loss of potentiation as
measured by a higher MPC4 value compared to NSC60339 (Table 4). Sulfonic
acid is negatively charged which would result in electrostatic repulsion with E67 if
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Table 4. Potentiation due to modification of the dihydroimidazoline and
central ring.

H
N
R2

O

R1
O
N
H

R2
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binding occurs at the hinge site. The basic nitrogen in the dihydroimidazolium ring
acting as a hydrogen bond donor appears to be required for potentiation. When
the dihydroimidazolium ring was shifted from a para (1,4) to a meta (1,3) position,
only a 2-fold increase in MPC4 was observed (Table 4). We then speculated that
only a single dihydroimidazolium ring is needed for potentiation. We identified a
lower scoring pose of NSC60339 at the hinge site in which only one
dihydroimidazolium ring is interacting at the hinge site (Figure 29). The lowerscoring pose has a score of -5.8 kcal/mol while the best-scoring pose has a score
of -7.8 kcal/mol, a difference of 2 kcal/mol. The training set of AutoDock Vina has
a standard error of 2.85 kcal/mol compared to the experimental binding affinities;
thus, a difference of 2 kcal/mol is insignificant in terms of docking calculations.130
Four compounds with one dihydroimidazolium ring were found to exhibit
improved permeability, accumulation of Hoechst H33342, and equal or improved
potentiation of novobiocin (Table 5). Two of the compounds (17h and 17i) contain
halo substituents, chlorine and bromine, on a benzene ring ortho (1,2) to the
dihydroimidazolium ring (Figure 30). The other two compounds (17o and 17p)
contain hydrophobic alkyl groups para (1,4) to the dihydroimidazolium ring (Figure
30). Further SAR analysis revealed that replacement of the central ring in
NSC60339 with an additional chloro, a nitro, methyl, and a bromo had similar MPC4
values (Table 4). It was only when a fluorine was used that a loss of potentiation
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Figure 29. Lower scoring docking pose of NSC60339 at the hinge site with only
one dihydroimidazolium ring interacting with AcrA.

Table 5. Four compounds with equal or improved EPI characteristics
relative to NSC60339.
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Figure 30. Four analogs with improved OM permeability, Hoechst H33342 uptake,
and equal or improved potentiation of novobiocin compared to NSC60339 was
observed (Table 4).
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was observed (Table 4). In addition, removal of the central phenyl ring for a more
conformationally flexible cyclohexyl ring or an acyclic core resulted in a loss of
potentiation (Table 6).
Compounds 17h,17i, 17o, and 17p had lower WT MIC / WT-Pore MIC ratios
than NSC60339 resulting in improved permeability (Table 5). Three of the
compounds also had lower ratios of MIC WT-Pore / MIC WT-Pore-DTolC cells
indicating that the compounds were less susceptible to efflux as an AcrAB-TolC
substrate and possessed less antibacterial activity (Table 5). Three of the 4
compounds also had improved uptake or accumulation of Hoechst H33342 and
equal or greater potentiation of novobiocin or erythromycin (Table 5). NSC60339
in addition to 17h and 17o were also found not disrupt the proton gradient across
the inner membrane (Figure 31). This was previously not assessed at the time
Table 1 was compiled. Valinomycin is an antibiotic that is known to disrupt
electrochemical gradients; thus, it served as a useful control to assess disruption
of the proton gradient across a membrane. 145
The four new compounds have an increased rigidity (fewer rotatable
bonds), more amphiphilic (hydrophobic and hydrophilic groups), and possess low
globularity (long, planar) (Table 7). These properties correlate with compounds
Table 6. Removal of central aromatic ring results in loss of potentiation.
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Figure 31. NSC60339 (1), 17h, and 17o do not disrupt the transmembrane
potential that mimics the proton relay across the inner membrane. Valinomycin
was used as a control.

Table 7. Structural Descriptors for NSC60339 and 4 analogs with improved
EPI characteristics
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that can accumulate across the OM in E. coli.146 Although, the compounds only
contain 2 secondary amines and no primary amines or ammonium groups. The
addition of an ammonium group has been shown to provide a Gram-positive
antibiotic with broad-spectrum activity.146

Conclusions
The application of homology modeling using templates from the CusB and ZneB
crystal structures and the extraction of multiple conformations from each model
using MD simulation led to the identification of 4 new compounds with several EPIlike characteristics. One of those compounds, NSC60339, is specific for E. coli and
changes the structure of AcrA in vivo; thus, the compound possesses a novel
mechanism of action not seen in the other inhibitors or MC-207,110 and MBX2319.
However, none of the compounds that bind AcrA can permeate the outer
membrane. Lead optimization of NSC60339 to 4 new analogs helped to overcome
the OM permeability barrier with improved EPI characteristics. Thus, the
application of artificial WT-pore cells is a novel innovation to identify new diverse
compounds that could later be optimized to improve their permeability.
Our next step is to continue to identify more potent diverse compounds that
bind AcrA and accumulate across the OM. To fulfill this step, we first need to
experimentally confirm the ligand binding site(s) on AcrA. In this study, we
proposed two possible sites, the hinge and MP, but others may exist. We chose to
use a combination of site-directed mutagenesis, tryptophan fluorescence
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spectroscopy, blind docking, and MD simulation to indirectly infer probable binding
site(s) on AcrA for two of the four compounds.
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CHAPTER II
IDENTIFICATION OF BINDING SITES FOR EFFLUX PUMP
INHIBITORS OF THE ACRAB-TOLC COMPONENT ACRA
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Some results from this chapter were originally published in a manuscript
from which I am a co-first author. The citations for the manuscript are listed
below.
•

•

Darzynkiewicz, Z. M.*; Green, A. T*.; Abdali, N.; Hazel, A.; Fulton, R. L.;
Kimball, J.; Gryczynski, Z.; Gumbart, J. C.; Parks, J. M.; Smith, J. C.;
Zgurskaya, H. I., Identification of Binding Sites for Efflux Pump Inhibitors of
the AcrAB-TolC Component AcrA. Biophysical journal 2019, 116 (4), 648658.
co-first author
In this work, I built a new homology model of the AcrA MP domain using a

different template from the previous chapter. The template represents a closer
homolog of AcrA that was missed when the previous models were made. I also
carried out MD simulation and RMSD-clustering to extract 29 conformations from
the model. I conducted blind ensemble docking and subsequent clustering of the
poses to identify the most common binding sites explored by NSC60339,
NSC227186, and novobiocin. I also carried out FTMap calculations to examine
additional possible binding sites missed by blind ensemble docking. Lastly, I wrote
and designed the logic of the manuscript that reconciled the computational and
experimental results. The experiments were carried out by members of Helen
Zgurskaya’s lab at the University of Oklahoma.

Abstract
The overexpression of multidrug efflux pumps is an important mechanism
of clinical resistance in Gram-negative bacteria. Recently, four small molecules
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were discovered that inhibit efflux in Escherichia coli and interact with the AcrABTolC efflux pump component AcrA. However, the binding site(s) for these
molecules is not known. Here, we combine ensemble docking with tryptophan
fluorescence spectroscopy, site-directed mutagenesis, and antibiotic susceptibility
assays to probe binding sites and effects of binding of for two of these molecules.
We conclude that clorobiocin (NSC227186) and SLU-258 (NSC60339) likely bind
at a site located between the lipoyl and b-barrel domains.

Introduction
According to a report from the Center for Disease Control and Prevention
(CDC), approximately two million illnesses and 23,000 deaths are caused by
antibiotic resistance each year in the United States alone.147 Some strains of
Escherichia coli are now resistant to at least six different classes of antibiotics and
strains of Pseudomonas aeruginosa are now resistant to all classes of antibiotics.1
One of the primary mechanisms for multidrug resistance in Gram-negative
bacteria such as E. coli and P. aeruginosa is the overexpression of multidrug efflux
pumps, which expel antibiotics taken up by the bacteria.1 In E. coli, the multidrug
efflux pump is AcrAB-TolC and its counterpart in P. aeruginosa is MexAB-OprM.
AcrAB-TolC consists of three proteins, AcrA, AcrB, and TolC, which upon
assembly span both membranes and the periplasm.12 A cryo-EM structure of the
assembled pump in the apo state was resolved at 16 Å resolution.29 Cryo-EM
structures of both the apo state and inhibitor (MBX2931)-bound state were both
recently resolved at 6.5 Å.39 In agreement with biochemical and genetic studies,
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these structural analyses showed that the complex has a stoichiometry of 3:6:3 for
AcrB, AcrA, and TolC, respectively.42, 49 Each protomer of the AcrB homotrimer
consists of both a transmembrane and a periplasmic domain, while each protomer
of the TolC homotrimer consists of a b-barrel domain and a mostly a-helical
periplasmic domain. The complex is assembled by the membrane fusion protein
AcrA. Six AcrA protomers interact as a trimer of dimers in the assembled pump,
connecting the inner membrane transporter, AcrB, to the outer membrane
component, TolC (Figure 1). 39
AcrA consists of four domains connected by flexible linkers: the a-helical
hairpin, lipoyl, b-barrel, and membrane-proximal (MP) domains (Figure 32).78 The
a-helical hairpin domain interacts with the coiled-coil domains of TolC. The lipoyl
and b-barrel domains are the most conserved features of diverse MFP proteins.43
The MP domain is contained primarily within the C-terminal region of the AcrA
sequence, but also includes an N-terminal b sheet. This highly flexible domain
binds directly to one monomer of the inner membrane transporter AcrB.39 The 6.5
Å cryo-EM structure of the apo complex revealed spacious gaps between each
AcrA dimer through which antibiotics might be inadvertently expelled into the
periplasm. However, in cryo-EM models with the inhibitor MBX2931 bound to AcrB
the gaps between AcrA dimers are absent and the channel in TolC is open, thus
allowing antibiotics and other efflux pump substrates to exit the cell (Figure 5).39
Whereas most efflux pump inhibitors target the transporter, AcrB, the
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F81
Site I

Site IV

SLU-258
Site II
Site VI

Site III

a-hairpin
lipoyl
b-barrel
MP

E67

F254
I252

K241
I343

W347

Site V

Figure 32. (A) Inhibitor binding sites predicted from blind ensemble docking of
SLU-258, clorobiocin and novobiocin (Sites I-III) and additional sites predicted by
FTMap (Sites IV-VI). Sites I, II, and III are located between the a-hairpin and lipoyl
domains, in the b-barrel domain, and between the b-barrel and MP domain,
respectively. Site IV is located between the b-barrel and lipoyl domain, and Sites
V and VI are located in the MP domain. For clarity, only SLU-258 is shown. (B)
Residues mutated individually to Trp for fluorescence quenching experiments are
labeled and shown as cyan spheres. The intrinsic Trp in wild-type AcrA, W347,
was mutated to Phe.
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assembly of the pump has been targeted by searching for molecules that bind to
AcrA as shown in the previous chapter. A combination of virtual screening,
antibiotic potentiation assays and surface plasmon resonance (SPR) led to the
discovery of four molecules that inhibit efflux in E. coli and interact with AcrA. Each
molecule potentiated the activity, i.e., decreased the minimal inhibitory
concentration (MIC), of the antibiotics novobiocin and erythromycin and bound
AcrA in vitro (Table 1). Using an in vivo proteolysis approach, it was also found
that the inhibitor NSC60339 (SLU-258) altered the structure of AcrA (Figure 26).
In the absence of SLU-258, cleavage by trypsin occurred at two sites, R296 and
K396, whereas addition of this inhibitor also resulted in cleavage at K346,
indicating that SLU-258 likely alters the structure of AcrA in a manner that
increases the accessibility of K346 (Figure 26). Subsequently, structure-activity
relationships inferred from a docked pose of SLU-258 to AcrA helped guide the
modification of the chemical scaffold of SLU-258 to develop second-generation
EPIs targeting AcrA (Figure 27). A further four synthesized analogs were identified
that demonstrated improved EPI characteristics (Table 5).
Despite possible interactions between inhibitors and AcrA, the binding
site(s) for these inhibitors remain to be definitively determined. Further
development of improved efflux pump inhibitors that target AcrA would benefit from
better binding site characterization and from a knowledge of allosteric
communication that might be inhibited by binding and disrupting pump assembly.
Several methods are available for the determination of binding site(s) to a
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protein. One method would be to determine an atomic-level structure of the
protein-ligand complex using X-ray crystallography.66 However, AcrA is
conformationally flexible and currently only one crystal structure exists that lacks
the MP domain.78 Determination of a co-crystal structure could thus be impractical
if binding occurs at the MP domain. Another approach could be nuclear magnetic
resonance (NMR) spectroscopy, but AcrA is quite large with a molecular weight of
41 kDa. The large size and flexibility of AcrA could make resonance assignments
of individual residues difficult making NMR a potentially impractical approach.47, 148
While X-ray crystallography and NMR would identify the binding site and mode for
a given inhibitor, another method would only provide information about the binding
site. This method couples site-directed mutagenesis with a binding assay such as
surface plasmon resonance (SPR) by mutating predicted binding site residues and
testing if the affinity decreases.149 However, the AcrA inhibitors bind with affinity in
the low to mid micromolar range and possibly in more than one binding site (Figure
20).69 Originally, two predicted binding sites were used to identify the inhibitors as
discussed in the previous chapter. The low affinity, possibility of more than one
binding site, and flexibility of AcrA may indicate that binding to AcrA is more driven
by conformational changes than direct contacts. In vivo proteolysis has already
shown that NSC60339 changes the structure of AcrA (Figure 26). The binding of
the inhibitors may be entropically, not enthalpically driven. Here we combine
structural modeling of AcrA and computational ensemble docking with tryptophan
(Trp) fluorescence spectroscopy, site-directed mutagenesis, and antibiotic
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susceptibility assays to examine potential binding sites and effects of binding of
efflux pump inhibitors by conformational changes.

Computational methods
A structural model of the AcrA monomer was generated from a partially
complete X-ray crystal structure of AcrA (PDB entry 2F1M)78 and a full-length
structure of MexA (PDB entry 2V4D)44 using MODELLER 9.17.99 The sequences
of full-length wild-type AcrA and MexA were aligned with the SALIGN algorithm in
MODELLER (Figure 33).150 The sequence of wild-type AcrA was then threaded
onto the 2F1M and 2V4D templates. One hundred models were generated and the
model with the lowest DOPE score was used for molecular dynamics (MD)
simulation.
The program MODELLER aims to construct three-dimensional models of
proteins by a method referred to as the satisfaction of spatial restraints.99 The
sequence to be modeled is first aligned to the sequences of the template structures
through a function such as SALIGN embedded within MODELLER.91, 151 In our
case, the template structures are AcrA and MexA. The alignment of the template
structures to the modeled sequence allow MODELLER to derive distance and
dihedral restraints from the template structures that will be used to build the
structural model of the sequence.151 Additional restraints such as preferences for
bond lengths and bond angles are taken from the CHARMM22 force field.151
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Figure 33. Sequence alignment of full-length AcrA, MexA (chain F from PDB
2V4D) and CusB (chain B from PDB 3NE5). The orange boxes indicate the extent
of the AcrA homology built from MexA.
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Restraints that encompass statistical preferences for dihedral angles and interatomic distances based on analysis of a representative set of known proteins
structures are also assigned by MODELLER.151 Additional restraints from various
experimental sources such as disulfide cross-linking, NMR NOESY restraints, or
cryo-EM density maps can also be added to help improve the accuracy of the
models.151 No experimental restraints were available at the time of our modeling.
All the restraints are then combined into an objective function, a function that is
designed to be minimized, by a combination of energy minimization and MD
simulation with simulated annealing.151 Energy minimization through a method
referred to as conjugate gradients allows MODELLER to identify a model that is
located at some minima of the objective function.151 Further sampling by MD
simulation with simulated annealing enhances the sampling and allows
MODELLER to more likely identify the model with the lowest objective function i.e.
the global minimum that is akin to the native state on a free energy landscape
(Figure 11). The lowest value of the objective function is the one that best satisfies
the spatial restraints assigned by the sequence-structure alignment.151 The
sampling of the objective function by MD simulation with simulated annealing is
based on a random search to identify the global minimum; thus, changes in the
initial conditions will lead to different models.151 Thus, we built 100 models that
claimed to satisfy the spatial restraints and each model was subject to further
evaluation by the DOPE score.
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DOPE, discrete optimized protein energy, is a knowledge-based or
statistical potential that estimates the free energy or potential of mean force by the
probability or likelihood that a given model approximates a representative set of
1472 crystallographic structures from the protein data bank (PDB).152 DOPE
estimates the probability of distances between all atoms types from all the amino
acids in the model in reference to the probabilities for the same distances obtained
from 1472 representative diverse structures from the PDB.152 The representatives
have a resolution of less than or equal to 1.8 Å and share a sequence identity of
less than 30% with each other. The DOPE score is then the negative logarithm of
the sum of the products of the probability distributions from all atom pairs for the
model (Pi,j model) and the selected experimental structures in the PDB (Pi,j,exp).152

𝐷𝑂𝑃𝐸 = −𝑘m 𝑇 ln (

𝑃#,K,O79:H 𝑟
𝑃#,K,:„… 𝑟

which is the definition of the potential of mean force in statistical mechanics and
the units are in kT. The terms i and j represent the atom types that define their
distance. Based on this statistical mechanical definition of the DOPE score, the
lower the score, the greater the accuracy of the model given the probabilities of
distances from the structures in the PDB. The DOPE score can be evaluated after
the modeling is complete; thus, it is independent of the objective function and can
be used to evaluate the best model prior to further calculations such as MD
simulation.152
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MD simulation was performed on the model with the lowest DOPE score to
explore the flexibility of the protein and discover potential binding sites. A 50 ns
MD simulation of the best-scoring model was carried out using the AMBER99SB
force field and TIP3P water model to describe the protein and solvent,
respectively.153, 154 Periodic boundary conditions were applied and a cutoff of 1.4
nm was used for real-space nonbonded interactions. The Particle Mesh Ewald
(PME) method with a grid spacing of 0.16 nm and the Verlet cutoff scheme were
used to describe long-range electrostatics.122 A long-range dispersion correction
was applied to the energy and pressure to account for truncation of the LennardJones interactions.119 All bonds were constrained with the LINCS algorithm, which
enabled the use of a 2-fs time step with the leapfrog integrator.111, 155 The model
was solvated in a triclinic box with a minimum of 3.0 nm between the protein and
the nearest face of the box. The charge of the system was neutralized with 3 Clions and the energy was minimized with a tolerance of 1000 kJ mol-1 nm-1 and a
step size of 0.01 nm. A two-step equilibration was carried out prior to data
collection. In the first equilibration step, the temperature was adjusted over 1 ns to
298 K in an NVT ensemble using a V-rescale thermostat with a time constant of
0.1 ps.156 In the second step, the pressure was adjusted over 1 ns to 1 bar using
a Parrinello-Rahman barostat with a time constant of 2 ps.157 During both
equilibration steps, harmonic restraints were applied to all heavy atoms of the
protein with a force constant of 1000 kJ mol-1 nm-2. Production MD simulations for
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data collection were carried out in the NPT ensemble without harmonic restraints.
All MD simulations were performed with GROMACS 5.1.2.109
All-atom RMSD clustering of the MD trajectory was performed with gmx
cluster to select conformations for ensemble docking.109, 127 Using an RMSD cutoff
of 0.4 nm, 29 conformations were selected. The inhibitors SLU-258, clorobiocin,
and novobiocin (Figure 34) were docked to each conformation with VinaMPI, a
massively parallel implementation of AutoDock Vina.138 The initial structures for
clorobiocin and novobiocin were obtained from the ZINC15 database and SLU258 was obtained from NCI Diversity Set V.75 The protonation state for each
inhibitor was taken as the major predicted state at pH 7 from the ZINC15
database.75 Clorobiocin and novobiocin were assigned a charge of -1 and SLU258 a charge of +2 (Figure 34). Hydrogen atoms were added to SLU-258 with
MOE 2016.100
The docking search space was centered at the center of mass of each
conformation and included the entire protein except for the tip of the 𝛼-hairpin
domain (Figure 35), which was excluded due to limits on the size of the search
space in AutoDock Tools.134 Each docking run was performed three times with an
exhaustiveness of 1000 and a maximum number of poses for ligand and protein
conformations of 25. The poses from all docking runs for each ligand were
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Figure 34. Chemical structures of (A) clorobiocin, (B) novobiocin, (C) SLU-258,
and (D) SLU-417.
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Figure 35. Search space used for docking. The dimensions of the box are 50 Å x
126 Å x 126 Å.
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combined and clustered based on the RMSD of all ligand atoms with a cutoff of
0.25 nm. The centroid poses from two of the largest clusters were selected as the
predicted binding sites. A third site referred to as Site I was also known as the
hinge site described previously (Figure 20A).
A single representative conformation obtained from RMSD clustering of the
50 ns MD simulation trajectory of the WT AcrA monomer was submitted to the
FTMap (http://ftmap.bu.edu/home.php) web server with default options.158
Clorobiocin and SLU-258 were docked separately to 29 conformations of
AcrA near Site IV, which is located between F81 and F254 since Site IV was not
identified by the blind ensemble docking. The same conformations of AcrA and
each inhibitor as the blind docking were used. The center of the docking search
space was the center of mass of F81 and F254 for each conformation with grid
dimensions 25 Å x 25 Å x 25 Å. The exhaustiveness was set to 10 and the
maximum number of binding poses for each conformation was 25. The center of
mass was calculated using the MDAnalysis Python package.159

Structural modeling of AcrA from MexA
We first generated a structural model of WT AcrA using the X-ray structures
of truncated AcrA and full-length MexA as templates. Residues 1-37 at the Nterminus and 380-397 at the C-terminus were excluded from the model because
neither template covered these regions (Figure 33). The sequence identity
between the MP domain of AcrA and MexA is 56% (Figure 36). In the 6.5 Å cryo84

AcrA-MP P A V G V V T V K T E P L Q L N P N A I L V P Q Q G V T R T P R G D A T V L V V G A D D K V E T R P I V
MexA-MP P E V G I V T L E A Q T V T V K Q K A I L A P Q Q G V T R D L K G Q A T A L V V N A Q N K V E L R V I K
AcrA-MP A S Q A I G D K W L V T E G L K A G D R V V I S G L Q K V R P G V Q V K A Q E V
MexA-MP A D R V I G D K W L V T E G L N A G D K I I T E G L Q F V Q P G V E V K T V P -

Figure 36. Sequence alignment and identity between the MP domain of the AcrA
homology model and the MP domain of MexA from PDB 2V4D. The sequence
identity is 56%.
EM structure of apo AcrAB-TolC, AcrA was also modeled using X-ray structures
of AcrA and MexA as templates.39 Alignment and Ca superposition of snapshots
from the 50 ns MD simulation of the WT model onto a single chain of AcrA from
the assembled complex revealed an overall RMSD for the whole protein of around
6 Å (Figure 37). However, the individual domain RMSDs were ~3 Å for the b-barrel
and MP domains and ~2 Å or lower for the hairpin and lipoyl domains (Figure 37).
Thus, most the motion of the protein occurs at the interfaces between the domains.
Ramachandran plots that depict the orientation of the backbone dihedral
angles and define the secondary structure of a protein reveal 3 outliers105: Gln372,
Asn232, and Asn239 (Figure 38). All three residues are located in the MP domain
and/or at the a-helix of the b-barrel domain. The a-helix of the b-barrel domain
and the MP domain was not determined in the X-ray crystal structure of AcrA78;
thus, these outliers may be steric clashes from poor side chain packing during
model construction. The outliers were absent after the energy minimization with
the steepest descent algorithm in GROMACS 5.1.2.109, 110 The Ramachandran plot
agrees with the plot for Model A with b-sheet being the dominant secondary
structure for AcrA. In addition, the DOPE scores for all the models was estimated
to be 1000 kT lower than Model A built with the CusB template (Figure 39). The
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a-hairpin
lipoyl
b-barrel
MP

Figure 37. (A) Superposition of the homology model of WT AcrA monomer onto
an AcrA protomer from the cryo-EM structure of the assembled AcrAB-TolC
complex. Colors: hairpin (red), lipoyl (blue), barrel (orange), and MP domain
(green), chain D from PDB entry 5V5S (gray). The linkers are shown in magenta
and were not included in the RMSD calculation of each domain. (B) Ca RMSD of
AcrA for the whole protein and for each individual domain with respect to the cryoEM model over the course of the MD simulation.

Model w/ lowest DOPE score

Model w/ MexA post- EM

Figure 38. Ramachandran plots with the lowest DOPE score before and after energy
minimization. Energy minimization included the full solvated and ionized system. Plots
were rendered using MOE 2016.
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Figure 39. DOPE score for all 100 models using the AcrA crystal structure (PDB
2F1M) and the MP domain from CusB (red) or MexA (black).
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lower scores indicate a greater probability of agreement with known experimental
structures. The lower score is likely due to the higher sequence identity of MexA
than CusB resulting in a better sequence-structure alignment and spatial restraints
used to derive the model.

Calculation of potential binding sites
Using the structural model of AcrA, a combination of computational methods
was used to locate potential binding sites. Twenty-nine conformations of WT AcrA
were extracted from an MD simulation trajectory using RMSD clustering for use in
blind ensemble docking of the efflux pump inhibitors SLU-258 and clorobiocin
(Figure 32 & 40). The efflux pump substrate, novobiocin, was also assessed
(Figure 40).
Three sites were selected by clustering of the docked poses by RMSD, which we
refer to as Sites I, II, and III (Figure 32A & 40). Site I is located at the interface of
the 𝛼-hairpin and lipoyl domains and has been found by site-directed mutagenesis
to be functionally important (Figure 21). When residues at Site I, such as E67,
were mutated to Ala, the minimal inhibitory concentration (MIC) of the antibiotics
novobiocin and erythromycin decreased, indicating that the mutations impair efflux
function and make the bacteria more susceptible to the antibiotics (Figure 21). We
found that binding of SLU-258 at Site I could result in a steric clash that would
inhibit AcrA oligomerization, which would presumably disrupt the assembly of the
full complex (Figure 41).
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F254
I252
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Figure 40. Three predicted sites from RMSD clustering of blind ensemble docking
for (A) clorobiocin and (B) novobiocin referred to as Site I, II, and III. Residues
mutated to tryptophan are E67, F81, I252, K241, F254, and I343. W347 was
mutated to Phe. Each ligand comes from a separate conformation, but only one
conformation is shown for simplicity.

Figure 41. SLU-258 results in a steric clash when docked at Site I (hinge site) of
AcrA that could prevent oligomerization.
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Sites II and III were the most highly populated sites in the ensemble docking of
each inhibitor (Figure 42). Site II is located in the b-barrel domain and Site III is
located between the b-barrel and MP domains (Figure 33A). Previously, it was
found that in vivo proteolysis of the assembled AcrAB-TolC pump with trypsin
resulted in a major fragment of AcrA (K46−R294/R296) (Figure 26). Upon addition
of SLU-258, a fragment corresponding to residues K46−K346 of AcrA was also
observed (Figure 26). These findings indicate that the inhibitor alters the structure
of AcrA, presumably making K346 more accessible to trypsin. K346 is located in
the MP domain near Site III (Figure 43). One possibility would be that inhibitor
binding at Site III changes the structure of AcrA. In the assembled complex, the
MP domain interacts with AcrB (Figure 10). If an inhibitor binds at Site III, it could
prevent the MP domain of AcrA from interacting properly with AcrB and thus
prevent assembly of the pump. Alternatively, the change in structure may result by
propagation from binding at another site to Site III allosterically.
To search for additional binding sites that may have been overlooked by
blind ensemble docking, we used the binding site identification program FTMap.
FTMap works in an analogous manner to blind ensemble docking with the
exception that small organic solvent molecules are used to map possible binding
sites using a molecular mechanical energy function.158 FTMap identified Sites I, II,
and III, but also identified three more sites located in the MP domain and between
the b-barrel and lipoyl domain (Figure 32A). One site, Site IV, is located between
the b-barrel and lipoyl domain. The other two sites, V and VI, are in the MP domain.
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Figure 42. Number of occurrences of docked poses in each cluster determined
from RMSD-based clustering of (A) SLU-258, (B) novobiocin, and (C) clorobiocin
from blind ensemble docking. The RMSD cutoff was 2.5 Å.
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Figure 43. Binding of SLU-258 at Site III between the β-barrel and MP domain
exists between two proteolytic fragments, K46-R296 and K46-K346, determined in
the previous chapter.
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Truncated AcrA lacking the MP domain binds SLU-417 and
clorobiocin
We first assessed the binding of clorobiocin and SLU-417 (Figure 34), a
derived analog of SLU-258, to a truncated construct of AcrA lacking the MP domain
(residues 45-312) using biolayer interferometry (BLI). Binding of SLU-417 to the
truncated construct was observed with responses similar to the full-length protein
(Figure 44), diminishing the likelihood that Sites III, V, and VI are major inhibitor
binding sites in AcrA. Clorobiocin was also found to bind the truncated construct.

Mutations in Site IV have the largest impacts on efflux pump
function
We carried out site-directed mutagenesis of selected residues near Sites I,
II, III, and IV (Figure 32B) and performed Trp fluorescence spectroscopy on the
mutants to detect inhibitor binding. Changes in Trp fluorescence can occur by three
different mechanisms: static quenching, dynamic quenching, and changes in the
environment.160 Static quenching occurs when a fluorescent molecule (such as

Figure 44. Biolayer interferometry (BLI) spectra for (A) SLU-417, an analog of
SLU-258, binding to full-length AcrA, (B) SLU-417 binding to a truncated variant of
AcrA lacking the MP domain (AcrA (45-312), and (C) clorobiocin binding to AcrA
(45-312).
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clorobiocin, novobiocin, and SLU-258) quenches fluorescence intensity through
direct contact with the Trp residue. Dynamic quenching occurs when excitation of
the fluorescent molecule transfers energy in the excited state from the Trp to the
molecule without direct contact. Changes in the local environment of Trp that result
in increased or decreased solvent exposure can also modify fluorescence
properties.160
Wild-type AcrA contains only one intrinsic Trp residue, W347, which is
located near Site III. Thus, W347 was mutated to Phe and the following residues
were mutated individually to Trp: E67W near Site I, K241W near Site II, I252W and
I343W near Site III, and F81W and F254W near Site IV (Figure 32B). E67, K241,
and I343 were chosen because they are on the surface of AcrA and may be close
enough for an inhibitor bound in each site to interact directly with each of these
residues through static quenching. F81, I252, and F254 were chosen because we
expect that they could interact indirectly with inhibitors through an allosteric change
in the local environment of the Trp or excitation energy transfer through dynamic
quenching (Figure 32A).
To determine whether these Trp mutations in AcrA affect functionality of the
efflux pump, we measured the MICs of selected antibiotics for strains carrying the
AcrA variants and compared them to the WT. We measured the MICs for
novobiocin, erythromycin, and tetracycline in cells with and without pores in their
outer membrane (WT and WT-Pore). All three of these antibiotics are AcrAB-TolC
substrates. The presence of pores diminishes the permeability barrier of the outer
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membrane, allowing antibiotic activity and the corresponding effects on efflux to
be assessed directly.142 Sodium dodecyl sulfate (SDS), which is also an AcrABTolC substrate, was used as a non-antibiotic control. All selected mutants were
expressed and retained at least partial efflux function compared to the wild-type
(Table 8). However, the mutant F81W (Site IV) exhibited the largest decrease in
MIC for each antibiotic, as cells carrying this AcrA variant were hypersusceptible
to antibiotics even with the native OM. In hyperporinated cells, which have
increased influx of antibiotics into the periplasm, E67W (Site I) provided weak
protection against antibiotics. All other AcrA mutants containing Trp substitutions
were functionally similar to the AcrA W347F variant and were 2-4 fold less active
than WT AcrA (Table 8). These results show that the F81W and E67W
substitutions decrease the activity of the AcrAB-TolC efflux pump. Thus, these two
residues are functionally important for efflux. E67 was already known to
functionally important with mutations to alanine and arginine (Figure 21). The other
residues are also functionally important, but to a lesser extent including residues
I343 and W347 at the MP domain.

Fluorescence of tryptophan residues in AcrA reports on binding
of inhibitors.
The fluorescence spectrum of apo WT AcrA consists of a single maximum
(𝜆OG„ = 330 nm, Table 9), which indicates that the single W347 is not exposed to
an aqueous environment but is buried in the protein.161 Substitution of W347 in
AcrA W347F abolished this maximum. The fluorescence emission spectra and
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Table 8. Antibiotic Susceptibilities of Wild-Type AcrA and Selected Trp
Mutants

a

NOV, novobiocin; ERY, erythromycin; TET, tetracycline; SDS, sodium dodecyl
sulfate.
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Table 9. Fluorescence properties of single Trp mutants of AcrA in the
absence and presence of inhibitors

a

, the wavelength of fluorescence emission maximum
, averaged tau intensities and amplitudes
c
, dissociation constants calculated based on quenching of tryptophan
fluorescence
d
, the Stern-Volmer quenching constant
e
, Clo, clorobiocin; SLU, SLU-258; Nov, novobiocin
b
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maxima of the F81W and F254W variants were similar to that of the WT protein,
suggesting that these Trp residues are also buried within the protein. Surprisingly,
the I343W mutant exhibited two distinct fluorescence emission peaks at 310 and
340 nm, indicating that this mutant adopts two states, in which this Trp residue has
different exposure to the buffer (Figure 45). Furthermore, these states differ from
that of the WT protein. All the remaining mutants have 𝜆OG„ values of 350 nm,
indicating that their Trp residues are exposed on the surface of AcrA and different
than the WT protein.
With the addition of clorobiocin or SLU-258 to the WT, 𝜆OG„ of W347
increased to 338 nm. Similarly, for the F81W and F254W mutants, 𝜆OG„ increased
to 338 nm for clorobiocin and 341 nm for SLU-258. Therefore, the binding of these
inhibitors to WT, F81W and F254W (Site IV) AcrA changed their Trp fluorescence
by exposing these residues to the solvent. At the same time, the fluorescence
intensity (quenching) of these AcrA variants decreased with increasing
concentrations of clorobiocin and SLU-258 (Figure 45). The greatest Trp
fluorescence quenching occurred for F81W (Site IV) and I343W (Site III) upon
addition of clorobiocin and SLU-258, followed by F254W (Site IV) (Figure 45).
F81W and I343W had quenching efficiencies of ~40-45% for SLU-258, and F81W
has an efficiency of ~40% with clorobiocin. These results indicate that binding of
SLU-258 and clorobiocin change the structure of AcrA. Quenching by I343W at
Site III is consistent with SLU-258 changing the structure of AcrA in vivo using
trypsin proteolysis (Figure 43). It is also possible that the inhibitor is in contact with
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Figure 45. Fluorescence of AcrA mutants carrying a single Trp substitution in the
absence of inhibitors (A) and quenching in the presence of increasing
concentrations of SLU-258 (B), clorobiocin (C), and novobiocin (D).
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each mutant residue concerned through a static quenching mechanism due to the
intrinsic fluorescence of clorobiocin and SLU-258 without AcrA (Figure 46). No
changes in the fluorescence maxima were detected for E67W (Site I), I252W (Site
III), and K241W (Site II) for clorobiocin suggesting that these solvent-exposed Trp
residues do not undergo large conformational changes in the presence of ligands
(Table 9). Small changes of 3 nm with E67W and K241W for SLU-258 indicate
that the binding poses of clorobiocin and SLU-258 may be different (Table 9).
Quenching by novobiocin was marginal for all the mutants, likely due to the low
intrinsic fluorescence of this compound (Figure 45D & 46).
The Trp fluorescence quenching was used to estimate the affinities of
clorobiocin and SLU-258 to different AcrA variants. We found that, independent of
the Trp position, both ligands have comparable micromolar affinity to the protein
due to the magnitude of the error bars, with clorobiocin binding to AcrA two to three
times more tightly than SLU-258 (Table 9). A similar affinity of SLU-258 to AcrA
(78 µM) was reported previously based on surface plasmon resonance (SPR)
measurements.69 Although, it should be noted the SPR measurements also found
clorobiocin to have a Kd of 213 µM.69 Fluorescence identified clorobiocin to bind
tighter than SLU-258, but the reverse was true using SPR. The experimental
affinity measurements for AcrA are not reliable for the determination of inhibitor
binding sites.
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Figure 46. Fluorescence of Clorobiocin, SLU-258, and novobiocin without AcrA.
F81W, F254W, and I343W exhibited the lowest intensities, amplitudes, and
lifetimes in the presence of clorobiocin and SLU-258 (Table 9). However, as
described above, the I343W oscillates between the low and high solvent exposure
which may also explain the proteolysis with trypsin (Table 9 and Figure 26). I343
is located in the MP domain, which is absent in the X-ray crystal structure of AcrA
and is known to be conformationally flexible.78 The MP domain is highly flexible in
vitro and can change conformation regardless of whether a ligand is bound.44 In
contrast, Site IV, which is flanked by F81W and F254W, was resolved in the crystal
structure and is therefore expected to be more rigid. Hence, fluorescence changes
near Site IV are more likely to be due to inhibitor binding.

F81W and F254W, both located in Site IV, are protected from
quenching when clorobiocin and SLU-258 are bound
To further examine whether clorobiocin and SLU-258 bind near F81W or
F254W (Site IV), we analyzed quenching of the Trp fluorescence by increasing
concentrations of potassium iodide with and without inhibitors. If an inhibitor binds
near F81W or F254W, fluorescence of the Trp concerned may be protected from
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iodide quenching by the inhibitor. Indeed, F81W was significantly protected (42%
reduction in quenching) from iodide by clorobiocin (Figure 47). Weak protection
by clorobiocin (15% reduction in quenching) was also observed for F254W (Figure
48). No significant changes in potassium iodide quenching were found for Trp
residues at any other positions for clorobiocin and SLU-258 (Figure 47 & 48).
In the presence of clorobiocin, Trp residues in F81W and F254W are more
solvent-exposed, as indicated by red shifts in the respective fluorescence spectra
(Table 9). Thus, it is unlikely that protection of iodide is a result of relocating these
Trp residues deeper into the protein structure due to its conformational change or
oligomerization. Clorobiocin is therefore likely to protect F81W directly from
quenching by iodide. The effect of SLU-258 was different, as its presence resulted
in somewhat enhanced quenching of F81W and F254W with iodide. Thus,
clorobiocin and SLU-258 may have different binding poses or interact with different
residues in AcrA that is not able to be observed in tryptophan fluorescence.

SLU-258 and clorobiocin likely bind near Site IV
The following observations all point to SLU-258 and clorobiocin binding at or
near Site IV:
(i)

Both inhibitors bind to an AcrA construct lacking the MP domain.

(ii)

F81W impairs efflux.

(iii)

Fluorescence changes upon binding the inhibitors to F81W and F254W
most resemble the corresponding changes in the wild-type.

(iv)

Both clorobiocin and SLU-258 interfere with the quenching of potassium
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Figure 47. Trp fluorescence in the absence (Apo) and presence of clorobiocin
(CLO) or SLU-258 (SLU) with increasing concentrations of potassium iodide (KI).

Figure 48. Trp fluorescence of E67W, K241W and I252W AcrA variants in the
absence (Apo) and presence of clorobiocin (CLO) or SLU-258 (SLU) with
increasing concentrations of potassium iodide (KI).
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iodide with F81W and F254W in Site IV.
These results provide evidence that Site IV is associated with clorobiocin
and SLU-258 binding (Figure 49). In the docked models the inhibitors engage in
largely different interactions with the binding site. Whereas the negatively charged
clorobiocin forms hydrogen bonding and electrostatic interaction with R183, in
contrast the R183 side chain is pointed away from the positively charged SLU-258
inhibitor (Figure 49). In addition, the hydroxy group of T205 forms a hydrogen
bonding interaction with clorobiocin but is oriented away from SLU-258.
Nevertheless, clorobiocin and SLU-258 both form hydrogen bonding interactions
with Q207, but clorobiocin also forms a hydrogen bond with the backbone of G185,
while SLU-258 form a hydrogen bond with the backbone carbonyl of H285 (Figure
49). Thus, Site IV, which engages in different interactions for clorobiocin and SLU258, provides the best explanation for the binding site location of SLU-258 and
clorobiocin.

Conclusions
A combination of computational modeling and experimental Trp
fluorescence spectroscopy has been used to identify likely binding sites of
clorobiocin and SLU-258 to the membrane fusion protein AcrA of the AcrAB-TolC
efflux pump in E. coli. Our findings point to Site IV, which is located at the interface
of the β-barrel and lipoyl domain, as the most likely binding site for the two
inhibitors. The F81W mutation in Site IV increased the susceptibility of antibiotics
to E. coli and this effect is correlated with the highest quenching of fluorescence
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Figure 49. Docked models of clorobiocin and SLU-258 (magenta) bound at Site
IV between the lipoyl and b-barrel domains, flanked by F81 and F254 (green
spheres). (A-B) Residues within 5 Å of each ligand are shown in green mesh. (CD) Residues in contact with each ligand are shown in cyan sticks and the
interactions are indicated by black dashes.

105

intensity of all Trp mutants. Both F81W and F254W mutants that flank Site IV
possessed 𝜆max values that are identical to the wild-type apo protein, with similar
shifts relative to the wild-type in the presence of each inhibitor. The lifetimes for
both residues were the shortest of all the mutants and they were the only two
mutants that interfered with quenching by potassium iodide (Table 9).
The mechanism of inhibition for both inhibitors remains unknown. However,
if the inhibitors indeed bind at Site IV, a conformational change might occur that
causes the protein to adopt a more closed state, which could interfere with
assembly of the pump. In the model of the complex, SLU-258 forms a hydrogen
bond with H285, and previous MD simulations have shown that H285 plays a role
in the pH-dependent conformational changes of AcrA.162 The role of pH may also
have influenced the different quenching observed for clorobiocin and SLU-258.
The pKa of an ionizable residue such as histidine can shift due to changes in the
microenvironment of the residue.163 In solution, histidine has a pKa of ~6 which per
the Henderson-Hasselbach equation indicates that ~50% of the molecules in
solution are protonated and deprotonated.105 If histidine is in a more hydrophobic
or buried environment, the pKa may shift to a lower value; thus, a greater
percentage of histidine will be neutral and deprotonated.105 The histidine residue,
H285, was predicted by the algorithms PROPKA and the Protonate3d module in
MOE 2016 to be ~6 in our AcrA homology model with MexA.100, 164 Both algorithms
rely on different methods of pKa prediction. Clorobiocin and SLU-258 are predicted
to be negatively and positively charged, respectively. Negatively charged
106

clorobiocin would interact more favorably with a protonated histidine that is
positively charged. In contrast, SLU-258 is positively charged and would interact
more favorably with a deprotonated and neutral histidine due to a lack of
electrostatic repulsion. The protonation state of histidine, clorobiocin, and SLU-258
could be one of the factors that could contribute to different binding poses for both
ligands and thus the different quenching behavior observed when potassium iodide
was added.
The determination of Site IV as the probable AcrA binding site for the efflux
pump inhibitors clorobiocin and SLU-258 provides only a coarse description of
ligand binding. The precise binding modes or poses are not able to be discerned
by our combination of blind ensemble docking and tryptophan fluorescence.
Moreover, standard MD simulations rely on fixed protonation states and thus pHdependent phenomena pose a challenge for simulation.165 A specialized
computational method referred to as constant-pH MD simulations has been
developed to explicitly incorporation protonation state changes and it has recently
been applied to sample the O-L transition in the inner membrane transporter
AcrB.165,

166

While constant-pH could be applied to discern binding mode

differences for both inhibitors bound to Site IV of AcrA, the binding modes could
still not be experimentally verified. To solve this problem in the future, an X-ray cocrystal structure of both inhibitors to the truncated construct of AcrA lacking the
MP domain could be solved. The MP domain is unlikely to be solved by X-ray
crystallography due to its flexibility.42,

44

With a crystal structure based on the
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orientation of the side chains and nonbonding interactions, the protonation states
could be inferred and binding pose differences between the two inhibitors could be
reconciled with the fluorescence data. MD simulation could be carried out on the
crystallographic poses and further rationalized with the fluorescence data. An
enhanced sampling method such as supervised MD, adaptive biasing force, or
umbrella sampling could also be implemented on the crystallographic poses to
estimate the free energy landscape of both inhibitors and dissect the differences
between them.107, 167 In the absence of crystal structures, multidimensional protein
NMR could potentially be carried out on the truncated construct with both inhibitors
and distance restraints using NOESY could be derived. The restraints could then
be used to determine the protein-ligand complex.168 A recent NMR method has
determined the protein-ligand complex for a ligand with millimolar affinity.169 All the
proposals are options that would extend and continue the work provided here.
Nevertheless, refinement of models of inhibitor binding to Site IV provided
here may still form the basis for identifying structure-activity relationships and
designing improved inhibitors with greater antibiotic potentiation activity using
computer-aided drug design.
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CHAPTER III
DISCOVERY OF NEW EFFLUX PUMP INHIBITORS WITH A
NOVEL CHEMICAL SCAFFOLD THAT INTERACT WITH THE
ESCHERICHIA COLI EFFLUX PUMP ADAPTOR ACRA
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The results from this chapter are in the process of being prepared for publication.
I designed the cheminformatics and docking workflow that predicted the 49
compounds that were subsequently tested by in vivo and in vitro experiments. I
also analyzed the results and reconciled the calculations and the experiments to
identify a novel chemical scaffold that binds AcrA and potentiates efflux pump
substrates. Experiments were carried out by Helen Zgurskaya’s lab at the
University of Oklahoma.

Abstract
The permeability barrier of the outer membrane and multidrug efflux are two
major contributors to antibiotic resistance in Gram-negative bacteria. Previously, a
Gram-positive antibiotic obtained broad spectrum activity by addition of an
ammonium group and was found to permeate the outer membrane. It was further
found that small molecules which are long and planar, rigid, polar, and amphiphilic
have a greater tendency to accumulate across the outer membrane. Thus, we
have filtered 13 million 3D structures of small molecules available on the ZINC15
database using structural descriptors that identify compounds with characteristics
likely to permeate the outer membrane. We then docked 1,427 compounds to four
possible binding sites on AcrA and selected the top compounds from all four sites
for experimental validation. Seven compounds were found to potentiate the
antibiotics and efflux pump substrates novobiocin and erythromycin in Escherichia
coli and bind AcrA in vitro. All seven compounds have an amino-cyclobutyl
pyrimidine scaffold. Lack of this scaffold fails to potentiate antibiotics. However,
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the seven compounds did not permeate the outer membrane which implies that
additional factors are needed to understand outer membrane permeability. In
addition, the seven compounds did not increase the accumulation of the
fluorescent probe and efflux pump substrate Hoechst H33342 implying the
compounds do not inhibit efflux, but the lack of antibacterial activity and lack of
potentiation in efflux-deficient cells for 5 out of the 7 compounds implies that
potentiation of novobiocin and erythromycin is efflux related. We propose using
electron density docking that the seven compounds likely potentiate by
displacement of the antibiotics from their binding site on AcrB.

Introduction
Multidrug antibiotic resistance is a global public health crisis that is leading
to the deaths of thousands of people every year.1 One of the primary causes of
resistance in Gram-negative bacteria such as Escherichia coli and Pseudomonas
aeruginosa is the overexpression of multicomponent molecular machines referred
to as efflux pumps.64 In E. coli, the efflux pump is a tripartite assembly called
AcrAB-TolC and its homolog in P. aeruginosa is MexAB-OprM.35
Models of the assembled complexes of MexAB-OprM and AcrAB-TolC have
been obtained using cryo-EM structures of AcrAB-TolC.29,

170

The pumps

contribute to multidrug resistance through a long-range allosteric transport
mechanism.39 An antibiotic traverses the outer membrane and first interacts with
the access pocket of AcrB in the periplasm.18 AcrB is a trimeric protein with
transmembrane domains embedded in the inner membrane and periplasmic
111

domains that exist in the periplasm.36 The binding of the antibiotic to the access
pocket of AcrB results in a conformational change that reveals a new binding site
referred to as the distal binding pocket.18,

171

Transfer of a proton from the

periplasm to Asp407 and Asp408 in the transmembrane domains of AcrB trigger
another conformational change that collapses the distal binding pocket and ejects
the antibiotic towards TolC for efflux out of the cell.36,

166

The series of

conformational changes in AcrB is referred to as a functional rotation mechanism.18
Functional rotation of AcrB in the assembled complex results in changes in AcrA
and TolC.39 AcrA exists as a trimer of dimers in the assembled complex that
contain spacious gaps between each dimer when no antibiotic is bound to AcrB.39
These gaps are sealed during antibiotic binding to prevent leakage during efflux.39
TolC is a trimeric protein composed of coiled-coil domains that form a closed funnel
leading out of the cell.29 The sealing of spacious gaps in AcrA leads to the opening
of the funnel in TolC allowing the antibiotic to exit the cell.39
Drugs that potentiate antibiotics and inhibit efflux by AcrAB-TolC have been
identified that interact with AcrA or AcrB.66,

69

MBX2319 is one example of an

inhibitor with a pyranopyridine scaffold that potentiates the antibiotics levofloxacin
and minocycline across a spectrum of clinically relevant Gram-negative bacteria
such as Escherichia coli, Salmonella enterica, and Klebsiella pneumoniae.66
MBX2319 was found using X-ray crystallography to bind the distal pocket of
AcrB.66 A series of analogs were derived from MBX2319 that exhibited improved
potentiation of levofloxacin.65,

66

The analogs prevent efflux through AcrB and
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compete for the distal binding pocket with an antibiotic.66 In contrast, inhibitors
such as NSC60339 were found to inhibit efflux and change the structure of AcrA
in vivo.69 A combination of site-directed mutagenesis and fluorescence quenching
identified the probable binding site of NSC60339 to AcrA.172 Based on the binding
site, NSC60339 could inhibit efflux through disruption of AcrAB-TolC assembly.
Several analogs were derived from NSC60339 and found to have improved
characteristics of an EPI (Table 5).173
Despite advances in the identification of inhibitors that inhibit multidrug
efflux in Gram-negative bacteria, the ability to discover new antibiotics and
inhibitors that function in Gram-negative bacteria is still limited.10, 76 One limitation
is the Gram-negative outer membrane that provides a permeability barrier to many
compounds.10 The outer membrane (OM) consists of an asymmetric hydrophobic
lipid bilayer combined with polysaccharide groups that are cross-linked by divalent
cations to create a charged external environment.17, 174 The lipid bilayer of the OM
contains outer membrane porins (OMP) such as OmpF and OmpC in E. coli that
provide a selective barrier for compounds to enter the cell.13 Recently, physicochemical molecular descriptors have been identified for compounds that permeate
the OM in E. coli and P. aeruginosa.146, 175 One of those descriptors is the presence
of an ammonium group.146 The addition of ammonium was able to provide a Grampositive antibiotic with broad-spectrum activity.146 Other descriptors include rigidity
(number of rotatable bonds), low globularity (long and planar), amphiphilicity, and
polarity (high dipole moment).146, 175 Long, rigid, amphiphilic, and polar molecules
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with ammonium groups tend to be successful at bypassing the permeability barrier
in Gram-negative bacteria.
MC-207,110 is one efflux pump inhibitor against E. coli and P. aeruginosa
that exhibits many of the physicochemical properties mentioned above.35 MC207,110 potentiates the activity of levofloxacin by non-competitive inhibition of
AcrAB-TolC unlike MBX2319.62 Previous computational models suggested that
MC-207,110 binds at a region called the G-loop on AcrB that separates the access
and distal binding pockets.40 The mutation of residues in the G-loop impairs
efflux.40 Surface plasmon resonance (SPR) experiments have also shown that
MC-207,110 can bind AcrA with micromolar affinity.69 In efflux-deficient cells, MC207,110 can disrupt the structural integrity of the OM and increase the
accumulation of levofloxacin.35 MC-207,110 is predicted to be di-cationic at pH 7.4
according to ZINC1575 and contains ammonium, two primary amines, and one
secondary amine (Figure 50). The structure has a polar character (dipole
moment > 8), low globularity (< 0.04), and is amphiphilic (amphiphilic moment >
4). These molecular descriptors are all indicative of a molecule that can permeate
the OM in E. coli. One difference is that MC-207,110 is conformationally flexible
with 10 rotatable bonds. Nevertheless, the high polarity and net positive charge
from the ammonium and primary amines may have contributed to MC-207,110
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Figure 50. (A) Chemical structure of MC-207,110 with amines shown in red. (B)
Molecular descriptors for MC-207,110 calculated with MOE 2016.
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being able to permeate the OM. An antibiotic, gentamicin, contains 3 primary
amines and can permeate the OM in WT and efflux-deficient cells.142 The polarity
and charge of MC-207,110 may prevent binding to the distal pocket which is lined
with hydrophobic phenylalanine residues.170 It may also help binding to AcrA.
Inhibitors that bind AcrA such as NSC60339 exhibit similar physicochemical
properties as MC-207,110: net positive charge, amphiphilic, low globularity, and
the presence of an amine (Table 7).173
In this work, we aim to identify new inhibitors that can permeate the OM in
E. coli, inhibit efflux, and interact with AcrA. We filtered 13 million 3D structures
from the ZINC15 database by log P, the presence of an ammonium group, rigidity,
globularity, dipole moment, and amphiphilic moment. We then docked the
compounds to an ensemble of conformations of AcrA from molecular dynamics
(MD) simulations to 4 possible binding sites: the probable binding site of
NSC60339 and three other possible sites that lowered the MIC of erythromycin
when residues at those sites were previously mutated (Table 8).172 Traditional
docking algorithms do not incorporate receptor flexibility into their calculations126,
but ensemble docking uses an ensemble of representative conformations of a
protein and docks a small molecule to all conformations to mimic a conformational
selection mechanism.126 We selected the unique compounds identified in the top
500 of all docking poses from all four binding sites for experimental validation
(Table 10).
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Table 10. Compound Selection Workflow
13 million 3D structures from
ZINC15
Filter by logP and molecular weight

Filter 1.8 million SMILES by
presence of ammonium salt.
Calculate descriptors for 22,842
structures
Filter based on defined thresholds of
descriptors
Dock 1,427 ligands to four sites on
AcrA
Select unique compounds in the top
500 from all four sites.
Experimental Validation
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Generation of small molecule library
The ZINC15 database contained 13,732,880 3D structures of small molecules as
of November 26, 2018, in their dominant protonation state(s) at pH 7.4.75
Antibiotics tend to have a higher molecular weight and a lower log P value than
other classes of drugs76; therefore, we removed compounds with a log P calculated
by ZINC15 greater than 3 resulting in 1,832,894 small molecules. We selected only
the small molecules with an ammonium group by identifying the SMILES tag
[NH3+]. This selection was chosen because previous work has shown that
antibiotics with an ammonium group bypass the OM better than other functional
groups.146 We then computed the molecular globularity, number of single rotatable
bonds, dipole moment, and amphiphilic moment for 22,842 small molecules using
MOE 2016.100 Alternative protonation and tautomeric states at pH 7.4 for each
molecule were included.

Filtering by molecular descriptors
The molecular globularity, glob, defines the deviation of the molecular
shape of the compound from a perfect sphere.146 The dipole moment is an
estimate of the degree of partial charge separation.105 The dipole moment is
estimated using the PEOE method which estimates electrostatic properties from
the molecular topology.175 The number of rotatable single bonds, b_1rotN, is the
number of bonds not found in ring systems and consisting only of single bonds.100
The amphiphilic moment, vsurf_A is a vector that points from the center of the
hydrophobic to the hydrophilic domain of a molecule.146The length of the vector is
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the strength of the amphiphilic moment.146 Small molecules that permeate the OM
should have a low globularity (glob<=0.14), be rigid (b_1rotN <= 4), polar
(dipole >= 5.5), and amphiphilic (vsurf_A >= 4.0). The threshold for all four values
was chosen by previous work.146, 175 A total of 1,427 compounds satisfied all four
thresholds.

Ensemble docking
We built a homology model of AcrA using a previously published protocol.172
We ran a 50 nanosecond MD simulation of the model and extracted 29
conformations using RMSD clustering.172 The simulation methodology is available
from previously published work and described in the previous chapter.172 We
docked 1,427 compounds to all 29 conformations of AcrA using Autodock
VinaMPI.138 Partial charges calculated from AMSOL by the ZINC15 database were
used for each compound.75 All compounds were docked to 4 binding sites. All four
sites were shown previously to be possible binding sites on AcrA for small
molecules.172 The docking search space for each site was specified by the centerof-geometry of a single residue at the center. The dimensions for each space was
25 Å x 25 Å x 25 Å with exhaustiveness of 10. For the site I, site II, site III, and site
IV, the following residues were selected, respectively: E67, K241, I343 and I252,
and F81 and F254. All residues were selected based on previously published work
and described in the previous chapter.172 For each site, we sorted the top 500
poses by their docking score, an estimate of the binding free energy.130 We then
selected only the unique compounds that were in the top 500 poses of all four
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sites. A total of 49 compounds were suggested for experimental validation, but only
34 were tested due to commercial availability.

Electron density docking
To test whether the six compounds that potentiate erythromycin could
inhibit efflux by competitive inhibition, we performed electron density docking with
MOE 2016.100 The 11839473 was not docked to AcrB since the modeled structure
from ZINC15 is identical to 65071797 (Figure 51). Erythromycin was determined
to bind the access binding pocket of AcrB by X-ray crystallography (PDB 3AOC).38
The residues of the access binding pocket that surround erythromycin include S79,
T91, S135, F136, M573, M575, F615, G616, F617, A618, G619, I626, F666, E673,
L674, D681, E683, G826, G861, and M862. We placed the six compounds into the
access binding pocket defined by the residues mentioned previously using the
crystal structure of AcrB bound to erythromycin. Erythromycin was removed and
docked with the same procedure. The compounds were placed using the electron
density of the crystal structure and assigned an energy score to define the
agreement between the simulated density of the docked compound and the
experimental electron density. The more favorable, lower the energy, the better
the agreement between the densities. The better the agreement of the densities,
we predict a greater likelihood that the compound could inhibit by competitive
inhibition through the access binding pocket. Docking of erythromycin had the
lowest score (Table 11). After placement, the compounds were refined using an
induced fit protocol that adjusts the ligand pose by the inclusion of side chain
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Figure 51. Alignment of the modeled structures from ZINC15 for 65071797 (blue)
and 11839473 (red).

Table 11. Electron Density Placement Scores for erythromycin (ERY) and
the six compounds.
Compound
ERY
56871955
985577577
65071797
24123034
36287038
58997260

Placement score (kcal/mol)
-98.7
-94.0
-88.0
-86.5
-86.0
-83.7
-77.9
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flexibility in the binding pocket. Refinement by induced fit produced 5 poses scored
using the GBVI scoring function in MOE 2016.176 The selected pose for each
compound had the lowest placement score. Structures for each compound with a
protonated/deprotonated nitrogen in the pyrimidine ring were docked. Both
structures were taken from the ZINC15 database.75 Two protonation states were
included for erythromycin and built using MOE 2016.100 Docking was carried out
with the AMBER10-EHT force field in MOE 2016 with AM1-BCC partial charges
assigned for the ligands.177

7 compounds potentiate novobiocin and erythromycin, bind
AcrA, but do not permeate the outer membrane
Out of 34 compounds tested, we identified seven compounds that potentiate
the antibiotics and the efflux pump substrates novobiocin and erythromycin in WTPore cells (Table 12). WT-Pore cells have ~2.4 nm size pores in the outer
membrane (OM) that allow small molecules to artificially overcome the
permeability barrier without affecting efflux.142 Despite filtering the ZINC15
database by structural descriptors that correlate with OM accumulation, no or
minimal potentiation of novobiocin and erythromycin was observed in WT cells
compared to WT-Pore (Table 13). A lack of potentiation indicates that the
compounds are impermeable to the outer membrane. Additional structural
descriptors may still be needed to adequately predict outer membrane
permeability.
Potentiation is quantified by a quantity referred to as the minimal
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Table 12. Antibiotic Susceptibility and Potentiation of Top Hits in WT-Pore
Cells.
Compounds MIC
MIC
MPC4 MPC4 MPC4
MPC4 AcrA
WT- DTolCWTWTDTolC- DTolC- Binder?
Pore
Pore
Pore
Pore
Pore
Pore
NOV
ERY
NOV
ERY
µM
µM
µM
µM
µM
µM
24123034
50
25
12.5
100
100
yes
³200
58997260
100
50
12.5
50
50
yes
³200
36287038
200
5025
>200
50
yes
³200
100
56871955
200
50
50
200
100
yes
³200
11839473
100
5025
100
100
yes
³200
100
65071797
200
25
25
100
100
yes
³200
98577577
200
50
50
200
100
yes
³200

Table 13. Potentiation of Top Hits in WT Cells
Compounds MIC
MPC4
WT
WT
NOV
µM
µM
24123034
58997260
36287038
56871955
11839473
65071797
98577577

³200
³200
³200
³200
³200
³200
³200

200
>200
200
>200
100
200
200

MPC4
WT
ERY
µM
200
200
NA
200
100
100
200
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potentiating concentration (MPC).61 We found that the seven compounds
potentiate novobiocin and erythromycin by at least 4-fold; thus, the quantity is
referred to as MPC4.

Novobiocin and erythromycin have minimal inhibitory

concentrations (MIC) of 32 µg/mL and 16 µg/mL, respectively.69 At concentrations
of 8 µg/mL and 4 µg/mL for novobiocin and erythromycin with a specific
concentration of one of the seven compounds, E. coli growth is inhibited indicative
of potentiation by the compounds. The lower the MPC4 value, the greater the
potency of the compound. The compounds 24123034 and 65071797 are the most
potent against novobiocin with concentrations of 25 µM (Table 12). 24123034, in
addition to 58997260, is also the most potent against erythromycin with
concentrations of 12.5 µM; however, 58997260 has an MPC4 value of 50 µM in
DTolC cells which is identical to the MPC4 in WT-Pore cells with novobiocin (Table
12). 58997260 potentiates novobiocin in efflux-deficient, DTolC, indicative that the
potentiation may not be due to interaction with AcrAB-TolC. None of the other
compounds potentiate in efflux-deficient cells, which indicates that the potentiation
of the remaining compounds is related to efflux inhibition.
All seven compounds not only potentiate novobiocin and erythromycin but
also bind AcrA using surface plasmon resonance (SPR) (Figure 52). AcrA binding
with SPR confirms the docking predictions that the compounds could bind AcrA,
but cannot provide details about the binding site(s) of the compounds. AcrA binding
also implies that potentiation could be due to efflux inhibition by disrupting the
assembly of the pump similar to NSC60339 discovered previously (Figure 26).
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Figure 52. SPR curves for the six compounds that bind AcrA. Compound
11839473 is identical to 65071797.
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The lack of intrinsic antibacterial activity also implies that potentiation is
likely not disrupting the proton gradient across the inner membrane. Disruption of
the proton gradient would indicate that a compound would have off-target effects
a part from AcrAB-TolC inhibition. The potentiation of novobiocin and erythromycin
and AcrA binding by the seven compounds thus appears to correlate with efflux
inhibition. Efflux inhibition for most efflux pump inhibitors (EPIs) is monitored by
the accumulation or increase in fluorescence of a dye referred to as Hoechst
H33342.62 Hoechst H33342 is an AcrAB-TolC substrate that enters the cell and
intercalates with DNA increasing fluorescence.62 WT cells with active efflux eject
the dye from the cell; thus, a decrease in fluorescence is observed. The addition
of a potential EPI in increasing concentrations should lead to an increase in
fluorescence if the compound inhibits AcrAB-TolC. The increase in fluorescence
indicates that more of the dye can remain in the cell to intercalate with DNA. For
all seven compounds, none increased the fluorescence of the dye indicative that
the efflux of the dye is not disrupted by the addition of each compound (Figure
53).

7 compounds may inhibit efflux competitively through
interaction with AcrB in the access binding pocket
The ability of the compounds to potentiate known efflux pump substrates,
lack of intrinsic antibacterial activity, and binding AcrA imply that the compounds
possess some EPI-like characteristics despite the lack of accumulation of Hoechst
H33342. One plausible explanation is that the compounds do not inhibit the
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Figure 53. Lack of accumulation of the fluorescent probe Hoechst H33342 for the
six compounds that bind AcrA. Compound 11839473 is identical to 65071797.
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assembly of the pump through binding AcrA analogous to NSC60339, but prevent
novobiocin and erythromycin from being effluxed through competitive inhibition.
The compounds could bind at the same binding pocket on AcrB as novobiocin and
erythromycin; thus, displacing the antibiotics and allowing them to remain in the
cell without impairing efflux. Currently, no crystal structure of AcrB with novobiocin
exists, but erythromycin has been shown to bind the access binding pocket of
AcrB.38
To predict whether six of the seven compounds could occupy the binding
pocket of AcrB, docking of the six compounds was conducted by placement and
scoring of the compounds into the access binding pocket using the available
electron density map from the AcrB crystal structure with erythromycin (ERY)
bound using MOE 2016. 11839473 was not docked since the modeled structure
from ZINC15 was identical to 65071797 (Figure 51). ERY was removed from the
binding pocket and subsequently docked and scored. Unsurprisingly, the
placement score of ERY into the electron density of the access pocket of AcrB was
the lowest energy compared to the other compounds; thus, serving as a reference
for our calculations. The agreement between the crystallographic and docking
pose of ERY had an RMSD of 1.6 Å (Figure 54). The disagreement between the
poses may due to the large size and flexibility of the molecule. 56871955 has the
lowest placement score of all six compounds and is predicted to bind the access
pocket by hydrogen bonding interaction with E673 and in proximity to F664 and
F666 (Table 11). 98577577 and 24123034 were also predicted to form a hydrogen
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Figure 54. Alignment of the crystallographic pose of erythromycin (pink) with the
best-scoring docked pose (blue). The RMSD of the alignment was 1.6 Å.
bond with E673 and reside near F664 and F666 (Figure 55). E673, F664, and
F666 are functionally relevant for efflux in that previous mutagenesis to alanine
resulted in increased antibiotic susceptibility and disruption of efflux.178 The ability
of 56871955, 98577577, and 24123034 to form interactions and reside near these
three residues analogous to ERY indicates that these three compounds could bind
the access binding pocket and displace ERY to potentiate its activity. 65071797,
36287038, and 58997260 are predicted to interact above E673, F664, and F666
and bind in between the residues F615 and R620 (Figure 55). The residues in
between F615 and R620 include residues F617 and G619. These residues
correspond to a region on AcrB referred to as the G-loop or switch-loop.38, 40 The
G-loop acts as a gate between the access and distal binding pockets.40,

179

Mutations of F615 and F617 into alanine have been shown to impair efflux and
increase antibiotic susceptibility.180 Moreover, a G616N mutation has been shown
to impair the efflux and transport of large drugs including erythromycin.181
129

56871955

ERY
E673

F666

F664

F664

F666

F664
65071797

98577577

F666

E673
R620

R620

F664

F615

F617

G619
F615
E673

58997260
R620

36287038

24123034

F666
F664

F666
F664

F617
F666
E673

E673

G619

F615
F664

F617
F666

E673

E673

Figure 55. The six compounds that bind AcrA may bind AcrB and reside near
functionally important residues of the access binding pocket (E673+F664+F666)
or residues of the G-loop (F615+F617+G619+R620). All residues listed except
R620, to the best of my knowledge, have been shown previously to affect drug
transport and efflux.
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The predicted binding of the six compounds by docking to the access pocket
using the electron density map reveals that the compounds could interact with key
functional residues at the access pocket and the G-loop (Figure 55). The results
provide molecular details of how the compounds could potentiate erythromycin by
displacement from its binding site without increasing fluorescence accumulation.
The compounds don’t displace Hoechst H33342, but novobiocin and erythromycin.
We expect that these results are also applicable to novobiocin despite the absence
of an AcrB crystal structure with novobiocin bound. Novobiocin is known to bind
AcrB.42 A molecule that enters the periplasm to bind AcrA can only interact with
AcrB through two known channels that both result in binding the access binding
pocket before efflux.37 Thus, if the compounds can displace erythromycin by
interacting with residues in the access pocket or hinder efflux by binding at the Gloop, then it can do the same for novobiocin.

Aminocyclobutyl pyrimidine scaffold is required for potentiation
of novobiocin and erythromycin
An interesting feature of these 7 compounds that potentiate antibiotics and
bind AcrA is that they all contain the same core scaffold (Figure 56). All the
compounds contain an aminocyclobutyl pyrimidine scaffold (Table 14). The
scaffold appears to be required for antibiotic potentiation, but not for binding AcrA.
Compounds such as 36579393 potentiate novobiocin and erythromycin with MPC4
values of 50 µM.
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Figure 56. Chemical structures of compounds that potentiate novobiocin and
erythromycin and bind AcrA.

132

Table 14. Structure-activity relationship (SAR) of compounds that bind
AcrA.
NH2
N
R
N

NH2
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Compounds such as 36579393 potentiate novobiocin and erythromycin
with MPC4 values of 50 µM and 25 µM, respectively, but do not bind AcrA (Table
15). When this scaffold is removed such as in 55628364, no potentiation of
novobiocin or erythromycin is observed (Table 16). When the scaffold is modified
such as alteration of the six-membered pyrimidine ring in 81717872 to a fivemembered ring, no potentiation is observed (Table 16). In 80737104, the primary
amine is removed from the pyrimidine ring and no potentiation is observed for
novobiocin (Table 16). The conservation of the aminocyclobutyl group for AcrA
binding and antibiotic potentiation appears to at least be qualitatively consistent
with docking predictions. As a representative example, we selected the bestscoring compound, 56871955, from AcrB docking to the access binding pocket to
observe how this same compound could interact with one of the four possible
binding sites on AcrA (Table 11). We observed that the hydrogen bonding
interactions appear to be localized to the aminocyclobutyl scaffold in all four sites
(Figure 57). We see a similar trend when 56871955 binds the access pocket of
AcrB (Figure 58). For AcrA and AcrB, the fluorine group appears to be exposed to
solvent and/or uninvolved in the formation of interactions necessary for binding;
thus, modification of this group may be an initial step towards developing new
analogs with an aminocyclobutyl pyrimidine scaffold that potentiates antibiotics. A
continued structure-activity relationship to further explore this scaffold could lead
to new inhibitors that potentiate antibiotics through competitive or allosteric
inhibition with AcrB or AcrA, respectively.
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Table 15. Structures with the aminocyclobutyl pyrimidine scaffold that do
not bind AcrA
NH2
N
R
N

NH2

R
O

WT-Pore MPC4
(µM) NOV
100

WT-Pore MPC4
(µM) ERY
50

200

100

100

100

200

100

100

100

>200

>200

200

200

N
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O
H
N

2158002
N

24695708
O
N

90425405
O
N

40735676
N

F

N
N
H

99815217
N

87676550
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Table 15. Continued.
R

N
N

WT-Pore MPC4
(µM) NOV

WT-Pore MPC4
(µM) ERY
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50
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N
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N

O
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O
N
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HN

N
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F

N
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Table 16. Structures of compounds that do not bind AcrA or potentiate
antibiotics
Compound
WT-Pore
WT-Pore
AcrA Binder
MPC4 NOV MPC4 ERY
(µM)
(µM)
200
NA
no
NH
N

N
N

NH2
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N N
N

>200

NA

no
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N
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Table 16. Continued.
Compound

NH

WT-Pore
MPC4 (µM)
NOV
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WT-Pore
MPC4 (µM)
ERY
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O
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Table 16. Continued.
Compound

F

WT-Pore
MPC4 (µM)
ERY
NA

AcrA Binder

NA
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NA

NA
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NA
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NH2

O
O
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O
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Cl

O
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N

HO

O

O
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O
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N
O

N

O

O
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Figure 57. Best-scoring docking poses for 56871955 bound to AcrA at Site I, II, III,
and IV.

T91
S79
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Figure 58. Contacts between 56871955 and AcrB are extensive for the
aminocyclobutyl pyrimidine scaffold. The fluorine group attached to the phenyl ring
appears to be unimportant for binding to AcrB.
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CONCLUSIONS, SIGNIFICANCE, AND FUTURE DIRECTIONS
We have for the first time identified efflux pump inhibitors that interact with
the periplasmic component AcrA of the AcrAB-TolC efflux pump in Escherichia
coli. We have identified inhibitors using a combination of virtual screening,
antibiotic potentiation, binding, and fluorescence accumulation assays. We found
that one of the inhibitors, NSC60339, can change the structure of AcrA in vivo
using trypsin proteolysis. No previous inhibitor shares this mechanism of inhibition
of AcrAB-TolC. Regardless, NSC60339 was still unable to bypass the outer
membrane (OM) of E. coli in wild-type cells.
Further development of a structure-activity relationship of NSC60339
identified at least four analogs with improved OM permeability and equal or
improved potency against novobiocin and erythromycin. However, the binding
site(s) on AcrA was not experimentally validated for NSC60339 or any of the
analogs. We thus performed blind docking calculations using multiple
conformations of an improved AcrA homology model in parallel with site-directed
mutagenesis and tryptophan fluorescence spectroscopy. We deduced that the
likely binding site for at least two of the discovered inhibitors, NSC60339 and
NSC227186, was located between the b-barrel and lipoyl domains of AcrA. We
further identified three other binding sites with residues that impair efflux upon
mutagenesis. The disruption of efflux by mutagenesis implies that these residues
are functionally relevant and thus could be targeted by new inhibitors to bind AcrA
and disrupt efflux.
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The four analogs derived from NSC60339 with improved OM permeability
contain structural traits consistent with accumulation across the outer membrane.
A previous study had found that small molecules which were long, planar, rigid,
polar, and amphiphilic, and contained an ammonium group were more likely to
bypass the outer membrane.146 The four analogs contained these traits except for
the ammonium group. To further discover new chemical scaffolds that bind AcrA,
we filtered 13 million structures from the ZINC15 database for compounds that
possessed these specific criteria. A total of 1,427 compounds were then docked
to the four possible binding sites on AcrA and the top compounds that were
predicted to bind all four sites were suggested for experimental validation. Seven
compounds with an amino-cyclobutyl pyrimidine scaffold were found to bind AcrA
and potentiate novobiocin and erythromycin. The compounds were not able to
bypass the OM permeability barrier indicative that more information is needed to
understand the structure-activity relationship of OM permeation. In addition, the
compounds lacked antibacterial activity and five of the compounds lacked
potentiation in efflux-deficient cells. The compounds also failed to increase the
accumulation of Hoechst H33342 implying that the compounds do not inhibit efflux.
However, since the compounds lack antibacterial activity and potentiation in effluxdeficient cells, it seems that the potentiation of novobiocin and erythromycin is
efflux-dependent. We thus propose that the compounds bind the erythromycin
binding pocket on AcrB and displace the antibiotic from the pump. The compounds
then do not displace the binding of Hoechst H33342.
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In this work, we have improved upon the modeling of AcrA using a multitemplate approach that uses both the AcrA crystal structure and MP domain from
the homologous MexA in Pseudomonas aeruginosa. AcrA has been shown to form
a partially functionally complex with MexB; thus, AcrA and MexA are structurally
and functionally similar.182 The AcrA structure from cryo-EM determined after our
modeling efforts used the MexA MP domain to fit into the cryo-EM density of
AcrAB-TolC.39
Further significance of this work is that not only have we shown, for the first
time, that efflux pump inhibitors can be identified to interact with AcrA, but they can
be identified with computational methods specifically ensemble-based virtual
screening and physicochemical descriptors. The previous two efflux pump
inhibitors discussed here, MC-207,110 and MBX2319 were discovered by wholecell high-throughput screens.35, 62 With our approach, novel compounds can be
initially identified in a less time-consuming and resource-intensive manner. In
addition, the computational methods used were successful because of a novel
experimental protocol that engineered E. coli cells to create 2.4 nm pores to allow
for more diverse compounds to enter the periplasm.142
In early-stage drug discovery, the two initial stages are referred to as hit
identification and lead optimization.76 In hit identification, potential drug candidates
are identified that function on your intended target. Afterwards, in lead optimization,
the candidates can be modified to improve the binding and/or potency to the
intended target to design a drug. Ultimately, our approach of utilizing comparative
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modeling, ensemble-based virtual screening, and physico-chemical descriptors in
combination with WT-Pore cells will help to accelerate the first phase of early-stage
drug discovery in bacterial cells: hit identification and take advantage of the new
regions and probable binding site identified on AcrA.
Further work still needs to be carried out to improve the potency for the lead
optimization of the inhibitors with the aminocyclobutyl scaffold and analogs derived
from NSC60339. To best achieve that goal, I propose that more extensive binding
site characterization on AcrA and knowledge of outer membrane permeability is
needed. The probable binding site on AcrA was indirectly inferred by tryptophan
fluorescence spectroscopy, a non-atomic resolution experimental method. The
method could not even distinguish the differences in the quenching of NSC60339
and NSC227186 when potassium iodide was added. The method could identify
the likely site or region, but not the specific poses of the inhibitors. The differences
in the poses could only be inferred by docking calculations. An X-ray or NMR
structure could further reconcile the docking calculations with the tryptophan
fluorescence spectroscopy data by providing atomic resolution. The biolayer
interferometry experiment showed that an analog of NSC60339 could bind AcrA
without the flexible MP domain. The MP domain was not determined in the X-ray
structure of AcrA due to its intrinsic flexibility.78 NSC60339 and NSC227186 could
be potentially crystallized with the truncated construct of AcrA and the differences
in the binding poses could be assessed.
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Currently, the most potent efflux pump inhibitors to date, the
pyranopyridines, have achieved their high potency in part due to the availability of
co-crystal structures.61 Thus, the determination of AcrA co-crystal structures could
further improve the lead optimization process. With co-crystal structures, predicted
relative free energies could be estimated using free energy perturbation (FEP) with
finite-size corrections due to the ligands being charged.183 Alternatively,
application of the attach-pull-release (APR) method could be used to assess the
absolute binding free energy.184 FEP or APR in conjunction with co-crystal
structures could propose new compounds with improved potency and potentially
accelerate the lead optimization process, but the outer membrane permeation
remains in question.
Since none of the seven compounds bypass the outer membrane even by
filtering the ZINC15 database for optimal physicochemical descriptors, more
knowledge is needed to explain the permeability of our inhibitors at the atomic
level. Previously, metadynamics simulations have been used to estimate twodimensional free energy profiles from a single pass through the outer membrane
porin OmpF in E. coli, but these simulations were carried out in homogenous model
membranes.185 The web server CHARMM-GUI allows for the automated
construction of native outer membranes in bacteria with proteins embedded.186, 187
Classical MD simulations have already been carried out with OmpF embedded in
a native outer membrane.17 Two-dimensional metadynamics could thus be carried
out to estimate the free energy of translocating our inhibitors across the highly
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charged outer leaflet and OmpF porin. Modifications could then be proposed and
assessed to observe if they lower the energetic barrier through the porin. A
combination of metadynamics with relative binding free energies using X-ray cocrystal structures of AcrA could lead to new analogs with improved potency that
bypass the outer membrane, potentiate antibiotics, and inhibit multidrug
resistance.
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